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Abstract 
The French Intensive Care Society organized its yearly Paris International Conference in intensive care on June 18–19, 
2015. The main purpose of this meeting is to gather the best experts in the field in order to provide the highest qual‑
ity update on a chosen topic. In 2015, the selected theme was: “Acute Renal Failure in the ICU: from injury to recovery.” 
The conference program covered multiple aspects of renal failure, including epidemiology, diagnosis, treatment 
and kidney support system, prognosis and recovery together with acute renal failure in specific settings. The pre‑
sent report provides a summary of every presentation including the key message and references and is structured 
in eight sections: (a) diagnosis and evaluation, (b) old and new diagnosis tools, (c) old and new treatments, (d) renal 
replacement therapy and management, (e) acute renal failure witness of other conditions, (f ) prognosis and recov‑
ery, (g) extracorporeal epuration beyond the kidney, (h) the use of biomarkers in clinical practice http://www.srlf.
org/5th‑paris‑international‑conference‑jeudi‑18‑et‑vendredi‑19‑juin‑2015/.
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Definitions and classifications
Progress in disease management requires a systematic 
measurement of the underlying components, its natural 
history and influence on outcomes. The extent to which a 
disease can be identified and classified influences its rec-
ognition as a distinct entity, e.g., diabetes or myocardial 
infraction versus a syndrome, e.g., sepsis or vasculitis. 
Until recently, acute renal failure was considered a syn-
drome classified in a simplistic framework of pre-renal, 
renal and post-renal conditions attributed to multi-
ple factors [1]. The absence of a standardized definition 
resulted in significant variation in reporting of this dis-
order and contributed to a lack of comparative data. 
Over the last 15 years, the syndrome has been renamed 
as acute kidney injury (AKI) and standardized diagnostic 
and staging criteria anchored to changes in serum cre-
atinine (SCr) and urine output (UO) to define AKI [2]. 
The RIFLE/AKIN and Kidney Disease: Improving Global 
Outcomes (KDIGO) classification systems are based on 
identifying a minimal change in renal functional param-
eters that are related to an outcome and a gradation of 
severity that associates with incremental risk of worse 
outcomes [3]. Based on these principles, the current 
diagnostic and staging criteria have been widely accepted 
and tested for validity in several settings (Table  1), and 
they have been shown to perform well in being associated 
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with adverse outcomes [4, 5]. However, our current crite-
ria are still lacking in several respects and require further 
considerations and enhancements [3]. While an increase 
in creatinine is the hallmark of current criteria, several 
patients present to the hospital or clinic with an elevated 
creatinine with no prior values available. The absence of a 
“baseline” creatinine makes it difficult to establish a refer-
ence point to determine whether a rise has occurred and 
also to determine whether the patient recovers. Several 
different approaches have been suggested to compensate 
for a missing baseline value including estimation of a glo-
merular filtration rate (GFR) based on population norms 
[6], use of the nadir creatinine during hospitalization as 
baseline; however, these have all been found to result in 
over- or underestimation of AKI [7]. We have proposed 
differentiating the “baseline” creatinine from the “ref-
erence” creatinine. The former value is used to define a 
patients underlying kidney health status and should be 
based on the lowest value form >90  days prior to the 
AKI event [8]. The reference creatinine is the value used 
to determine the diagnosis of AKI and should be within 
90 days of the event and can be the lowest value in that 
time period closest to the event that is being identified. 
This approach allows patients to be classified as having 
de novo AKI, AKI on chronic kidney disease (CKD) or 
AKI with unknown prior kidney health status. Transient 
increases in creatinine values are associated with better 
prognosis than persistent changes (>48 h); however, their 
risk of mortality is higher than those without any change 
in creatinine [4, 9]. The current definitions also do not 
include a decrease in creatinine as a criteria for AKI. 
Patients with an elevated creatinine that subsequently 
declines have been considered as community-acquired 
versus developing AKI during the hospital stay (hospital-
acquired) and have a better prognosis [10]. In critically 
ill patients, factors influencing creatinine measurements 
including volume of distribution are often overlooked, 
leading to an under appreciation of the degree of renal 
dysfunction and delays in management [11]. Changes in 
UO have now been validated in several studies as early 
and sensitive criteria for AKI [12, 13]. However, in prac-
tice systematic measurement and recording of UO have 
been difficult and often urinary catheters are not placed 
given the risk of infection. The availability of several bio-
markers of kidney injury has created excitement in offer-
ing new tools for recognition and management of AKI. 
Table 1 AKI scoring
See Ref. [234]
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Several biomarkers have been shown to have predictive 
ability in recognizing kidney damage earlier than creati-
nine but have not entered mainstream use as yet [14]. We 
have proposed considering biomarkers as functional (e.g., 
serum creatinine, serum cystatin C, UO) and damage 
markers (e.g., Kim-1, NGAL, TIMP2 and IGFBP3) and 
measure them in combination to improve the diagnos-
tic categorization and permit more guided interventions 
[15]. These approaches will allow determination of a bio-
marker-positive creatinine negative stage as a measure 
of subclinical AKI. It is evident that while we have made 
significant advances in defining and staging AKI, there is 
much that is need to be done. We have the tools, knowl-
edge and drive to continue to explore these areas with the 
goal to improve the lives of our patients. 
RFR in normal and diseased kidney
Kidney function has been evaluated on the basis of GFR. 
Although average values of GFR have been identified for 
healthy subjects, there is no such a concept of normal 
GFR in the single individual. GFR represents a single-
point assessment of kidney function that may be influ-
enced by several factors and may not be a reliable marker 
of true filtration capacity since it remains in normal 
ranges until 50% of nephrons are lost [16, 17].
Renal functional reserve (RFR) represents the kidney 
capacity to increase GFR in response to physiological or 
pathological stimuli. RFR can be clinically assessed by oral 
protein load or intravenous amino acid infusion and is 
defined as the difference between peak “stress” GFR after 
oral or i.v. protein load and the baseline GFR [18]. RFR 
and baseline GFR can be significantly different in subjects 
with different characteristics (Fig.  1). For patients with 
renal mass less than 50%, baseline and max GFR are often 
the same, unless a very low protein diet is in place [19].
RFR may be a reliable marker of the extent of “recruita-
ble” GFR under renal stress. Thus, its reduction could 
be the earliest sign of both kidney frailty among healthy 
individuals and kidney damage after a single kidney 
injury.
RFR could be taken into account to establish a new 
stage of CKD. This stage may be named “stage 0” in case 
of a diminished RFR in the presence of a normal base-
line GFR. The rationale for adopting RFR as the clinical 
parameter to diagnose “stage 0” CKD relies precisely on 
the clinical evidence that RFR reduction is the earliest 
subclinical sign of kidney function decline. This could be 
a situation, resulting in development of subsequent overt 
CKD and long-term complications. In many clinical sce-
narios, RFR reduction has been reported to be associated 
Fig. 1 RFR and baseline GFR according to patients characteristics
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with reduced kidney function, and disease progression, 
earlier than GFR decline: RFR declines along with the 
progression of CKD, among pregnant women, those who 
present mild-to-moderate hypertension have lower RFR 
compared to normotensive pregnant women, hyperten-
sive obese patients present a low RFR, in normotensive 
patients with systemic sclerosis with normal renal func-
tion and no urinary abnormalities, an abnormal RFR 
has reported to be associated with a greater than 5-year 
reduction in creatinine clearance, microalbuminuria and 
development of systemic hypertension, among male kid-
ney donors, four weeks after nephrectomy, the GFR of 
the remaining kidney increase significantly, but GFR fails 
to raise after a protein load, demonstrating that although 
GFR is normal RFR has been lost.
As in CKD, the main topics on AKI perspectives and 
future directions include the prevention, earliest possi-
ble diagnosis and accurate prognosis estimation [2]. As 
the RFR has not been validated during the curse of AKI, 
it cannot be used for its diagnosis; moreover, it has not 
been evaluated the time extent that it takes for RFR to 
return to its “best possible” levels. At this point, it has 
not been established if renal function returns to its best 
possible baseline immediately after the AKI trigger has 
stopped, or if it exists a period of time in which dysfunc-
tional, but yet viable nephrons remains dysfunctional, 
thus being possible to create a concept such as “stunned 
nephrons” the same way stunned myocardium represents 
a well-recognized entity [20].
Moreover, RFR measurement is also valid in critical 
care scenarios. RFR may be useful on the evaluation of 
response to diuretics (i.e., patients with a lower RFR most 
likely will not respond to diuretic) the same way alveolar 
recruitability measurements indicate the extent in which 
high PEEP may actually improve oxygenation among 
acute respiratory distress syndrome (ARDS) patients, and 
to evaluate the initiation of renal replacement therapy 
(RRT), since patients with a low RFR much more prob-
ably will require RRT [21].
Taking this into account, it is reasonable to add a new 
“susceptibility stage” also in the evaluation of AKI, since 
identifying an stage 1 AKI does not allow to identify and 
stratify the risk of AKI on the base of objective, single-
value criteria. Also, an “susceptibility stage” AKI may be 
used to indicate the patients that, after AKI, have lost its 
baseline RFR and thus remains susceptible to a new AKI 
episode, even in the absence of elevation of SCr or tubu-
lar damage biomarkers levels [22].
In conclusion, RFR is an interesting concept, and it 
represents an objective and dynamic measurement of 
renal function that may be useful on the early detec-
tion of kidney susceptibility for either acute or chronic 
kidney injury. It may also be used to stratify renal risk, 
evaluate the best treatment maneuver, and measure 
both functional renal recovery after AKI and renal dis-
ease progression in the case of CKD. It remains unclear 
whether or not its measurement under critical conditions 
may be valid, whether RFR value may be used to predict 
response to specific therapeutic maneuvers susceptibility 
to nephrotoxic drugs, and the extent of its value to prog-
nosticate long-term renal loss after a single AKI. In this 
context, more prospective clinical trials on the evaluation 
of the forenamed applications for RFR [23].
Epidemiology of AKI in the ICU: Are there any 
changes?
Over the last decade, AKI has come to prominence as 
a major contributor influencing outcomes in critically 
ill patients. With the development of the RIFLE/AKIN/
KDIGO diagnostic systems [3], several reports have 
described the epidemiology of AKI in the ICU. These 
have ranged from descriptions of administrative data 
sets, retrospective analysis of single- and multicenter 
cohorts and prospective cohort studies [24–27]. It has 
been difficult to compare the data across centers; how-
ever, some common themes have emerged. The incidence 
of AKI is now believed to be significantly higher than 
previously believed with over 50% of patients in the ICU 
developing stage 1 AKI at some point during the course, 
while stages 2 and 3 AKI are considerably less and RRT 
requirement is approximately 10% (Table  2). The stag-
ing system has been demonstrated to be a good predic-
tor of outcomes with an increasing risk of mortality and 
resource utilization with higher stages regardless of the 
setting. Risk factors have included increasing age, pres-
ence of heart failure, liver failure and CKD and anemia 
and exposures to nephrotoxic agents including antibiot-
ics, NSAIDS and contrast. Infections, sepsis, shock, need 
for mechanical ventilation and surgery are well recog-
nized as high-risk settings for the development of AKI 
[28]. There is increasing recognition that patients may 
present to the ICU with AKI (community-acquired) or 
develop it during the hospital stay (hospital-acquired). 
The latter is associated with a worse prognosis and is 
often iatrogenic in nature [10]. Management strategies 
continue to reflect supportive measures focusing on fluid 
delivery, diuretics, avoidance of nephrotoxic agents and 
RRT for the most severe cases; however, there have not 
been any specific measures targeted to the kidney that 
have been successful [29]. There is increasing recogni-
tion that fluid accumulation and overload contribute to 
adverse outcomes although it is uncertain whether this 
is causal. Renal recovery from ICU AKI has been vari-
ably reported as there are no standard definitions in this 
regard. There is a growing concern that AKI contributes 
to a significant burden of CKD, and long-term follow-up 
Page 5 of 40Bellomo et al. Ann. Intensive Care  (2017) 7:49 
studies report poor renal outcomes. Two large prospec-
tive multicenter international studies provide additional 
evidence of the heterogeneity of AKI in ICU patients and 
report significant differences in risk factors etiology and 
management and outcomes based on available resources. 
Bouchard et al. [25] have shown that patients in emerg-
ing countries were more likely to have glomerulonephri-
tis (GN) and acute interstitial nephritis, while those in 
developed countries had higher reported rates of pre-
renal AKI, sepsis and acute tubular necrosis. Residence 
in an emerging country was associated with more than 
a twofold increase in hospital mortality and a threefold 
lower rate of renal recovery in survivors. Hoste et al. [24] 
found similar results with a significant relationship to the 
underlying gross national income. Based on the accu-
mulated evidence so far, it is evident that AKI continues 
to be major problem for critically ill patients worldwide 
[30]. Identification of high-risk patients coupled with 
early diagnosis facilitated by emerging biomarkers and 
surveillance through electronic medical records are being 
proposed as opportunities to improve outcomes [31]. 
Strategies to prevent AKI and its consequences with tar-
geted interventions are sorely needed; however, it will 
require continued multidisciplinary team efforts to opti-
mize and standardize AKI management to make a differ-
ence in this devastating complication.
Place of renal biopsy in the ICU
AKI results from several systemic aggressors such as sep-
sis, shock, nephrotoxic drugs and major surgery. Indeed, 
these aggressors were observed in a vast majority of ICU 
patients with SCr elevation analyzed in the BEST study 
[26]. An article described a series of 19 consecutive 
patients who died of septic shock and were systematically 
biopsied immediately after death [32]. The renal lesions 
on pathological showed various degrees of acute tubular 
injury, vascular leukocytic infiltration, fibrin deposition 
and apoptosis. Another study reported similar lesions 
[33]. Thus in the setting of AKI factors, a uniform pat-
tern of renal lesions (most often referred as acute tubular 
necrosis even though this term is an oversimplification) 
is reproducibly observed. As no modification of treat-
ment can be derived from this pattern, renal sampling 
cannot be advocated in such patients in clinical routine.
However, using AKI staging criteria in the ICU set-
ting should not lead to the assumption that all patients 
with acute SCr elevation have actually AKI. Indeed, 
some patients may suffer from a more specific «nephro-
logic» form of acute renal failure whose prompt diagnosis 
and treatment are crucial. In the BEST cohort of criti-
cally ill patients with SCr increase, 12% of the patients 
had “other” factors than usual AKI factors identified [26]. 
Reviewing all renal biopsies performed in a nephrology 
department for acute renal failure, Uezono et al. observed 
among patients aged 65 years and older, 71% had a final 
diagnosis of crescentic GN [34]. In a series of 49 biopsies 
in patients with renal failure and acute infectious endo-
carditis, the most common biopsy finding was necrotiz-
ing and crescentic GN (53%), followed by endocapillary 
proliferative GN (37%) [35].
Two recent studies described the diagnostic yield of 
renal biopsy in ICU patients in whom the diagnosis of 
AKI was doubtful [36, 37]. These retrospective stud-
ies were performed in France on a 10-year period on 15 
ICUs. They retrieved “only” 133 biopsies (native kidneys 
in 124), indicating that this procedure was performed 
rarely (more than 100,000 patients having being admit-
ted in these ICU during the study period). In Augusto 
study, in nearly 90% of cases, biopsy was performed 
percutaneously under ultrasonographic guidance, a few 
patients having CT-scan-guided or surgical biopsy. The 
rate of adverse events in the two studies ranged from 12 
to 22%, and the rate of serious events (shock or require-
ment for >2 red cell packs) was being similar at 12% with 
Table 2 Incidence of AKI in critically ill patients
Screened (AKI)
Year N ICU # Patients RIFLE/AKIN/KDIGO Creat/UO Incidence (%)
Hoste 2006 7 5383 RIFLE Creat and UO 67
Ostermann [12] 2007 22 41,972 RIFLE Creat 35.8
Ostermann [13] 2008 22 22,303 AKIN Creat 35.4
Bagshaw [14] 2008 57 120,123 RIFLE/AKIN Creat and UO 37.1
Joannidis [15] 2009 303 16,784 RIFLE/AKIN Creat and UO 35.5
Mandelbaum [16] 2011 7 14,524 AKIN Creat and UO 57
Nisula [17] 2013 17 2091 AKIN Creat and UO 39.3
Liborio [18] 2014 1 18,410 KDIGO Creat and UO 55.6
Kellum [19] 2014 8 32,045 KDIGO Creat and UO 74.5
Hoste [2] 2015 97 1802 (1032)* KDIGO Creat and UO 57.3
Bouchard [9] 2015 9 6647 (745)* AKIN Creat 19.2
Page 6 of 40Bellomo et al. Ann. Intensive Care  (2017) 7:49 
one death overall. This high frequency of serious adverse 
events is tenfold higher than observed in the nephrology 
setting. In one of the studies, the rate of adverse event 
was significantly increased when the platelet count was 
below 200 G/L [36]. Transjugular biopsy may represent 
an interesting alternative to percutaneous sampling in 
high-risk patients even though no study with this tech-
nique has been dedicated to ICU patients. On native 
kidneys, the two studies showed a similar diagnostic 
yield, with around half of the patients having a specific 
diagnosis other than acute tubular necrosis. These diag-
noses give a very interesting insight into what should be 
considered in ICU patients with acute elevation in SCr 
beyond AKI. The most frequent diagnoses were crescen-
tic glomerulopathy with vasculitis (most patients having 
a final diagnosis of ANCA-associated vasculitis), throm-
botic microangiopathy and acute GN (associated with 
endocarditis in most cases). Interestingly, a few patients 
had end-stage renal lesions on the renal biopsy, show-
ing that they had been initially misdiagnosed as acute 
renal failure. The result of the biopsy was judged as hav-
ing an impact on treatment in between 41 and 71% of the 
cases (reflecting variation in how an impact was defined). 
Notwithstanding, in these two studies whether the final 
diagnoses could have been established using alternate 
approaches such as serum antibodies screening panel 
or biopsies at other sites than the kidney was not dis-
closed. These alternate approaches may be of high value. 
For example, in a study, a pre-biopsy clinical diagnosis 
of ANCA-associated GN was 100% correct showing the 
usefulness of ANCA testing [34].
In one of these studies, some factors were observed 
associated with a greater likelihood of having a patho-
logical diagnosis other than acute tubular necrosis: any 
extrarenal sign that evokes a systemic disease (i.e., arthri-
tis), absence of any usual AKI factor before creatinine 
rise, occurrence of renal creatinine increase before hos-
pital admission and any abnormal result on autoimmune/
microangiopathic screening [36]. These factors may be 
helpful to identify patients in which particular attention 
should be paid to the cause of renal dysfunction. Renal 
biopsy may be then considered if a thorough noninvasive 
approach had failed, and weighing the high risk of hem-
orrhagic adverse events.
Evaluation of renal blood flow by renal Doppler
Despite our increasing ability to support vital organs and 
resuscitate patients, the morbidity and mortality of AKI 
remain high in the ICU. The ability to predict the occur-
rence of AKI is crucial for the development of preventive 
strategies. Early diagnosis of AKI requires markers that 
are sensitive and easily applicable in clinical practice. The 
use of Doppler ultrasonography to assess renal perfusion 
is increasing in many kidney diseases and in the ICU. 
The Doppler-based renal-resistive index, which is a sim-
ple, rapid, noninvasive and repeatable marker, could be 
a promising tool to detect early patients, which are the 
most at risk of developing AKI in ICU and to distinguish 
transient from persistent AKI. Moreover, the resistive 
index could also be useful to guide therapeutic strategies 
to improve kidney perfusion at the bedside. The recent 
progress in ultrasound with contrast-enhanced ultra-
sound (CEUS) gives the opportunity to assess not only 
the kidney macrocirculation but also the kidney micro-
circulation in the ICU. CEUS could be a precise and 
reproducible way to evaluate renal perfusion in ICU. Fur-
ther studies are required to validate CEUS in ICU and to 
establish whether there is a correlation between changes 
in CEUS-derived indices and markers of renal function 
and outcome. CEUS is currently a research tool, but per-
haps in the future CEUS could assess the renal microcir-
culation at the bedside in the usual clinical practice.
Old and new diagnostic tools: how to use these 
in clinical practice
Introduction
Kidney function is in ICU patients traditionally evaluated 
by SCr and UO. These parameters are also used in the 
current KDIGO definition for AK (Fig. 2) [38].
Urine output
UO is probably the most readily available parameter for 
assessment of kidney function. The KDIGO classification 
requires hourly measurement of UO. Since ICU patients 
generally have a urinary bladder catheter, this require-
ment is easily met.
Unfortunately, several extrarenal factors can lead to 
false-positive or false-negative readings of kidney func-
tion. For instance, kinking of the urinary catheter may 
falsely indicate oliguria, while use of diuretics can give a 
false impression of good kidney function. Also, varying 
time intervals between UO recordings may hinder cor-
rect interpretation of the KDIGO criteria.
Serum creatinine
In non-ICU patients, SCr is predominantly determined 
by urinary clearance. However, in ICU patients altered 
production and volume of distribution of Cr will also 
affect its concentration. Cr is metabolized from creatine, 
which is released at a relative constant rate from muscles. 
However, bed rest and critical illness polymyoneuropathy 
will decrease muscle mass and so lower SCr. Also, vol-
ume resuscitation and increased volume of distribution 
will dilute SCr. Furthermore, changes in clearance will 
only be translated with a delay in SCr. As a consequence, 
single-point SCr may underestimate kidney function.
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For these reasons, AKI is defined by a change in SCr 
(Fig.  2). This requires the knowledge of a baseline SCr. 
In case this is not available, an MDRD-derived baseline 
value is proposed.
UO and SCr: the KDIGO criteria
AKI is staged on the worst of either SCr or UO criteria. 
This suggests that a patient classified on UO criteria has 
similar AKI severity and outcomes as when defined by 
SCr. However, several studies have shown that UO cri-
teria are more sensitive and associated with better out-
comes; and when a patient meets both SCr and UO for a 
certain stage, outcomes are marked more worse [13].
AKI sniffer or electronic alert for KDIGO stages
Several small and observational studies have shown 
that early intervention can improve outcomes. The use 
of electronic tools that alert when KDIGO criteria are 
met can so be of help. Wilson et  al. could not show a 
difference in outcomes in a hospital-wide setting [39]. 
A finding that may be explained by the absence of 
changes in care follows the alert. We found in our ICU 
that a sniffer alert leads to more and earlier interven-
tions and also a trend for less progression of AKI [40]. 
These conflicting findings may be explained by the ICU 
versus hospital-wide setting, but also by single-center 
design.
Kidney function or GFR
In out-patients, creatinine clearance (CCr) or estimated 
GFR (eGFR) can be assessed by simple equations such 
as MDRD or CKD-EPI. Alterations in muscle mass and 
volume of distribution limit the validity of these in ICU 
patients, which explains why eGFR is not adequate in 
ICU patients [41].
Measured urinary Ccr (Urinary Cr × Urinary volume)/
(Scr ×  time) over a 2 to 24-h time interval is therefore 
still the only reliable and simple way to assess kidney 
function in ICU patients.
Cystatin C
Cystatin C is a small protein produced by nucleated 
cells and eliminated by GFR. It behaves therefore simi-
lar to SCr, but is less dependent on muscle mass. In ICU 
patients, cystatin C will detect AKI 1–2  days earlier 
before SCr. However, it performed worse to SCr in car-
diac surgery patients. At present, the price (5–10 times 
that of SCr) also limits its daily use.
Fig. 2 KIDGO definition for AKI
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Pre‑renal AKI or transient AKI
There are several urinary indices for transient AKI. Most 
commonly used are urinary  Na+, fractional excretion of 
 Na+ (FENa) and FE of urea. Studies on their use showed 
conflicting results. Currently, we can therefore not rec-
ommend their use.
AKI detection before GFR decrease: damage
Before actual decline of GFR with resulting changes in 
SCr and UO, the kidney is exposed to stress and damage. 
Several biomarkers can indicate this and so may help in 
early recognition of AKI.
In burn patients, proteinuria is strongly associated with 
the development of AKI. In expert hands, the so-called 
urine sediment score can also indicate the risk of AKI.
At present, we have also two new biomarkers at our 
disposal: NGAL and TIMP-2*IGFBP7. Many others such 
as KIM-1 and chitinase-3-like protein 1 (CHI3L1) are 
under evaluation. These biomarkers allow more early 
identification of AKI, but also provide us new insights 
into the pathogenesis of AKI. In addition, they may indi-
cate use of RRT, renal recovery and long-term outcomes. 
Detailed info on their use will be discussed in the chapter 
on the pro–con debate on these biomarkers.
Old and new drugs: diuretics
Physiological effects of diuretics might help in mitigat-
ing renal injury. Furosemide acts in inhibiting the active 
 Na+/K+/Cl− co-transport pump on the luminal cell 
membrane surface of the medullary thick ascending limb 
of Henle loop. Tubular sodium reabsorption is an expen-
sive mechanism accounting for the larger part of the oxy-
gen consumption in an outer medulla already exposed to 
ischemic damage. Both animal and human studies dem-
onstrated diuretics to limit active sodium reabsorption 
ultimately decreasing both relative medulla hypoxia and 
oxygen consumption (Fig. 3) [42, 43]. Additionally, furo-
semide has been shown to attenuate apoptosis following 
ischemia–reperfusion injury in experimental model [44].
These theoretical benefits are, however, still to be vali-
dated in clinical setting. Thus, although widely used [27, 
45], diuretics have failed to demonstrate any benefit in 
preventing AKI, limiting the risk of RRT or fastening 
renal recovery [46]. In a recent systematic review assess-
ing the influence of diuretics in 876 patients, diuretics 
use was not associated with survival (relative risk 1.02; 
95% CI 0.86–1.19) or with reduced need for RRT (RR 
1.12; 95% CI 0.93–1.34) [46]. Cohort studies [27] and 
randomized trials [47] even suggested diuretics to be 
harmful in specific subgroups. Lack of adequately pow-
ered randomized controlled study (RCT) and variables 
unaccounted for such fluid balance changes or cluster-
ing effect are, however, to be taken into account when 
interpreting these negative results. Several advances in 
this field are to be expected.
First, as stated above, diuretics lack of efficacy has to 
be tempered down with regard to the high risk of bias 
in available studies. Large and adequately randomized 
control trials in AKI patients are currently ongoing 
[NCT01275729, NCT00978354; last accessed on June 20 
2015] and should put an end to remaining uncertainties 
in field.
Additionally, several specific uses of diuretics are being 
evaluated. Loop diuretics gain access to tubular lumen 
through active secretion, and their action is therefore 
dependent of tubular function [48]. Response to loop 
diuretic stress test might reflect degree of tubular injury 
and has been assessed in way to evaluate short-term 
renal prognosis. In a preliminary study, Chawla and col-
leagues demonstrated furosemide stress test to be a 
potent predictor of progression to AKI stage III or need 
for RRT [48, 49]. Moreover, performance of diuretic test 
for these purposes was higher than that of most serum 
or urinary biomarkers [49]. Although encouraging, it 
must be noted that progressors toward AKI stage III had 
lower urinary output [48], were more likely to have oligu-
ria before diuretic test and had more frequently an AKI 
stage II [49]. Performance of the furosemide stress test 
was not adjusted for these confounders, and additional 
studies are therefore needed to confirm these promis-
ing results. The RENALGUARD system has been devel-
oped in way to achieve high UO with diuretics while 
simultaneously maintaining fluid balance via real-time 
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Fig. 3 Changes in renal oxygen consumption following loop diuret‑
ics. In human or animal, use of diuretics is associated with higher 
renal medulla PO2 (mmHg), lower R2* BOLD MRI signal (Hz, 1/s) sug‑
gesting a higher oxygenation and lower renal oxygen consumption 
(RVO2, ml/min) in various conditions. *Results from selected studies 
(Brezis et al. Am J Physiol Renal Physiol 1994; Textor et al. J Am Soc 
Nephrol 2009; Warner et al. Invest Radiol 2011; Redfors et al. Intensive 
Care Med 2009; Sward et al. Intensive Care Med 2005). R2* is believed 
to be correlated with deoxyhemoglobin and therefore inversely cor‑
related with tissue oxygenation
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crystalloid compensation [50]. This system has been 
tested with interesting results in preventing contrast-
associated nephropathy (CAN) [50]. Respective influence 
of this device-led “forced diuresis” and of changes in uri-
nary creatinine excretion following diuretics use remains, 
however, to be delineated. This device might nevertheless 
be useful in specific niches requiring increased tubular 
flow and avoidance of dehydration to limit tubular injury 
such prevention of specific drug nephrotoxic effects or 
tumor lysis syndrome. Last, this device may provide 
opportunities for physiological research in allowing 
assessment of renoprotective effects of diuretics while 
ensuring neutral fluid balance. The last and most obvious 
potential interest of diuretics remains in limiting fluid 
overload. Increasing number of evidences pointed out 
the deleterious effects of positive fluid balance [51]. Not 
only recent studies underlined the poor outcome associ-
ated with positive fluid balance, but also they underlined 
the negative impact of positive fluid balance on various 
organs, including kidneys. Thus, renal congestion, inter-
stitial edema and subsequent changes in renal perfu-
sion are likely to participate in AKI development. In this 
regard, diuretics are first and above all already potent and 
validated drugs in allowing fluid balance adjustment.
Despite being widely used since half a century, uncer-
tainties regarding potential interests of loop diuretics 
in AKI patients remain. The available evidences argue 
against routine use of diuretics at bedside in preventing 
or treating AKI. Physiological and preliminary studies, 
however, clearly underline potential renal benefits of loop 
diuretics. Whether these theoretical benefits may trans-
late into clinically relevant benefits is yet to be proven.
Optimizing arterial pressure in patients with septic shock 
to prevent acute renal failure in ICU?
During septic shock, optimizing arterial pressure to pre-
vent acute renal failure remains a challenge for intensiv-
ists. The latest Surviving Sepsis Campaign guidelines [52] 
recommend (grade 1C: strong recommendation based on 
low level of evidence) that mean arterial pressure (MAP) 
should be targeted above 65 mmHg. However, there are 
few evidence-based data to support this threshold, as far 
as organ perfusion and dysfunction are concerned. The 
guidelines therefore temper this target by highlighting 
that “optimal MAP should be individualized as it may 
be higher in patients with atherosclerosis and/or previous 
hypertension than in young patients without cardiovascu-
lar comorbidity.” Shock resuscitation is a subtle balance 
between the risk of hypotension that would be responsi-
ble for organ hypoperfusion and subsequent dysfunction, 
and an excessive vasoconstriction associated with higher 
MAP target that requires increased vasopressors infusion 
rates, which would also result in organ hypoperfusion. 
Therefore, the way to prevent acute renal failure, while 
avoiding complications related to higher MAP and 
higher vasopressor need, would be to determine low and 
high MAP thresholds for resuscitation of septic shock 
patients.
Is it possible to determine a low MAP threshold to prevent 
acute renal failure for resuscitation of shock patients 
with sepsis?
Several studies investigated the effects of a MAP level on 
acute renal failure. Thus, in a retrospective cohort study 
of 274 septic patients, Dünser et al. [53] showed that, if 
there was a linear association between the time when 
MAP was below 60 mmHg during the first 24 h after ICU 
admission and 28-day mortality, the need for RRT was 
highest when MAP was below 75  mmHg. The authors 
therefore suggested that a higher MAP could be neces-
sary to maintain renal function. More recently, Legrand 
et  al. [54] showed that diastolic arterial pressure during 
the first 24 h after ICU admission was significantly lower, 
along with a higher central venous pressure, in patients 
who would develop acute renal failure.
Is it possible to determine a high MAP threshold to prevent 
complications related to a higher MAP and higher 
vasopressor needs for resuscitation of shock patients 
with sepsis?
Several prospective studies attempted to increase MAP 
by increasing norepinephrine infusion rates, but most of 
them included a small number of patients, with a short-
term follow-up, and none reported beneficial effect on 
renal function. In a post hoc analysis of 290 patients of 
a multicenter trial in which MAP was maintained above 
70 mmHg during shock, Dünser et  al. [55] showed that 
a MAP ≥ 70 mm Hg was not associated with increased 
mortality, but elevating MAP above 70  mmHg by 
increasing vasopressor infusion rates was associated to 
the development of disease-related events and increased 
28-day mortality. Poukkanen et  al. [56] later prospec-
tively confirmed in 423 patients with severe sepsis that 
vasopressor load was higher in patients with progression 
of acute renal failure.
In the SEPSISPAM trial [57], 778 patients with septic 
shock were stratified according to previous hypertension 
history and were treated with “low” (65–70 mmHg) ver-
sus “high” (80–85  mmHg) MAP target. In patients with 
previous hypertension treated with the high MAP tar-
get, there was significantly less renal failure—as defined 
by the doubling of plasma creatinine (38.8 versus 52.0%, 
p  <  0.05)—and less requirement for RRT between day 
1 to day 7 (31.7 versus 42.2%, p < 0.05). Conversely, for 
patients without prior hypertension, there was no ben-
efit to increase MAP target. As a reminder, there was no 
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difference for 28-day mortality, whatever the MAP group, 
and the occurrence of de novo atrial fibrillation was more 
frequent in the group treated with a higher MAP, most 
likely due to the higher vasopressor requirements.
The pathophysiological mechanisms of sepsis-induced 
acute renal failure are still a matter of debate. When arte-
rial pressures are low, renal autoregulation adaptation 
is lost and renal vascular resistances are increased, with 
subsequent renal hypoperfusion and ischemia. How-
ever, acute renal failure may still occur during hyperdy-
namic sepsis despite increased total renal blood flow, 
suggesting that other mechanisms are involved. Renal 
cortical microcirculatory flow is also impaired from the 
early stages of sepsis, before the renal perfusion pres-
sure (RPP) decreases. Several mechanisms are therefore 
likely to lead to sepsis-induced renal dysfunction, includ-
ing hypoperfusion, venous congestion, microcirculation 
alterations, but also mechanisms independent of hemo-
dynamic impairments, like inflammation and oxidative 
stress.
Conclusion
Although the exact pathophysiological mechanisms, but 
also the weight of each mechanism, are still debated, 
increasing MAP during septic shock might therefore 
benefit to patients with previous hypertension and pre-
vent acute renal failure. However, the increase in MAP is 
associated with increased vasopressor load, which in turn 
may increase adverse events and especially cardiac side 
effects.
Alkaline phosphatase: serendipity and the discovery of its 
renal‑protective properties
From a putative antisepsis agent to a renal-protective 
therapy currently investigated in a large phase II clini-
cal trial. Alkaline phosphatase (AP) is a dephosphorylat-
ing enzyme naturally occurring in the human body. The 
enzyme is located in several organs, including the kidney, 
liver, intestines, bone and placenta, where it is involved 
in, for example, bone mineralization, regulating of intes-
tinal barrier function and disease prediction. Next to its 
physiological role, AP plays a role in host defense and 
innate immunity. The anti-inflammatory role of AP was 
already demonstrated in the late nineties by Poelstra 
et al., who found that inhibition of endogenous AP in rats 
exposed to a sublethal dose of gram-negative Escheri-
chia coli resulted in significant higher mortality rates. 
This observation was confirmed by several other in vivo 
studies. Exogenous placental and intestinal AP improved 
survival rates, reduced systemic peak cytokine and nitric 
oxide levels and prevented liver and lung damage during 
systemic inflammation in mice. In sheep, the adminis-
tration of intestinal AP attenuated plasma interleukin-6 
levels and improved gas exchange during fecal sepsis, 
whereas intestinal AP enhanced thrombocyte counts in 
endotoxemic piglets. These effects are all attributed to 
dephosphorylation and thereby detoxification of lipopol-
ysaccharide (LPS), a key player in the pathogenesis of 
sepsis.
Clinical trials with biAP
Considering the profound anti-inflammatory effect in 
the preclinical tests and its presumed mechanism of 
action, sepsis trials with AP in men were initiated. First, 
bovine-derived intestinal AP (biAP) was administered 
to healthy volunteers and severe sepsis patients to assess 
the pharmacokinetic properties and confirm safety [58]. 
Subsequently, a multicenter phase II clinical trial was 
conducted with 36 patients with severe sepsis or septic 
shock admitted to the ICU. Patients were randomized to 
receive biAP or placebo intravenously for 24  h. No sta-
tistically significant effects of biAP on plasma cytokine 
levels or other systemic inflammatory parameters were 
observed, but in a subpopulation of patients with AKI 
(protective effects appeared to be present [59]. Treat-
ment with biAP significantly attenuated the increase in 
median plasma creatinine levels and the urinary excre-
tion of a marker of proximal tubule injury, glutathione-
S-transferase A1. Also, the need for and duration of RRT 
tended to be less, whereas patients without a diagnosis of 
AKI at inclusion were less likely to develop AKI (Fig. 4). 
Although these findings were not statistically signifi-
cant, due to the small number of patients, based on these 
results the renal effects of biAP were further explored 
in a second phase II clinical trial. Again, 36 patients 
with severe sepsis or septic shock and evidence of early 
AKI were randomized to biAP or placebo intravenously 
for 48  h. Patients treated with biAP showed improved 
endogenous CCr and reduced the need for, and dura-
tion of RRT, confirming its renal-protective effects. In 
addition, biAP infusion attenuated the urinary excretion 
of renal injury markers interleukin-18 and kidney injury 
molecule-1 compared to placebo [60].
Human recombinant alkaline phosphatase
As the protective effect of AP was demonstrated in a 
limited number of patients only, results needed to be 
reconfirmed in larger trials. However, administering 
bovine-sourced material to humans is less desirable due 
to the risk of immune reactions and challenges obtaining 
bovine spongiform encephalopathy (BSE)-free sources 
of AP. Therefore, a human AP was developed. By replac-
ing the crown domain of a human intestinal AP with the 
crown domain of human placental AP, a recombinant AP 
(recAP) was obtained that is highly stable, biologically 
active and has beneficial pharmacokinetic properties 
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compared to biAP. The protective effect of recAP was 
recently demonstrated during LPS-induced inflamma-
tion in a human renal cell line and during several forms 
of AKI in  vivo [61]. Preliminary data suggest that the 
detrimental molecules ATP and ADP, released during 
cellular stress, are also targets of recAP as they are both 
rapidly converted into the cytoprotective adenosine.
Following these encouraging results, clinical pharma-
cology, safety and tolerability were evaluated in healthy 
volunteers. In this randomized, double-blind, placebo-
controlled phase I clinical trial, single and multiple 
ascending intravenous doses recAP were well tolerated 
and could be administered without any safety concerns 
[62]. Subsequently, the efficacy of recAP is currently 
being investigated in an adaptive, multicenter, phase 
II clinical trial in patients with sepsis-associated AKI 
(NTC02182440). This two-stage trial will recruit a total 
of 290 patients. In the first part, the most effective dose 
out of three different doses of recAP will be determined, 
which will be further investigated in the second part of 
the study. While endogenous CCr during the first 7 days 
after start of administration of recAP is the primary end-
point, incidence and duration of RRT over 28  days and 
the subsequent occurrence of CKD will also be recorded, 
as well as various non-kidney-related clinical parameters.
RRT in severe AKI: an overview
Introduction
Untreated severe AKI in critically ill patients is associ-
ated with high mortality, and renal replacement therapies 
(RRTs) represent the cornerstone of the management 
of severe AKI. However, despite the dramatic evolution 
in technology for RRT, the mortality of AKI is still high. 
In 2015, a meta-analysis of 765 studies showed that the 
pooled incidence of AKI in hospital patients was 22% in 
adults and 14% in children and that the global mortality 
of AKI requiring RRT was 46% [30]. The aim of this brief 
narrative review is to describe the efficacy and clinical 
indications for different modalities of RRT in severe AKI 
patients.
Modality: continuous RRT and intermittent hemodialysis
Different modalities of RRT have been and are used in 
the treatment of AKI, including continuous RRT (CRRT), 
intermittent hemodialysis (IHD), sustained low-efficiency 
dialysis (SLED) and peritoneal dialysis (PD). A worldwide 
survey [26] showed that CRRT was the most prevalent 
initial modality for AKI patients (80.0%), followed by 
IHD (16.9%), and PD and SLED (3.2%) (Table 3).
Compared with other modalities, CRRT was consid-
ered as the predominant form of RRT in the ICU due to 
accurate volume control, steady acid–base and electrolyte 
correction, and the benefits on hemodynamic stability. 
However, although there might be some bias in patients 
selection, many randomized controlled trials (RCTs) and 
meta-analyses showed no difference in mortality between 
CRRT and IHD [63–65]. However, a meta-analysis [66] in 
2013 reported that CRRT was associated with lower rate 
of dialysis dependence than IHD, and similar results were 
also found in a recent large cohort study [67]. Higher rate 
Fig. 4 RRT requirement and AKI occurence after biAP in patient with sepsis
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of dialysis dependence indicated that the real cost of IHD 
might be significantly higher than previously thought; in 
contrast, CRRT might be more cost-effective [68].
Technique: hemofiltration, hemodialysis 
and hemodiafiltration
If CRRT is being applied to the care of an ICU patient, 
the issue of preferred technique arises. As shown in 
Fig.  5, continuous hemofiltration (convective solute 
clearance), hemodialysis (diffusive solute clearance) and 
hemodiafiltration (combined convective and diffusive 
solute clearance) are the main solute clearance tech-
niques in different kinds of CRRT. At this time, most 
clinicians appear to prefer hemofiltration or hemodiafil-
tration in critically ill patients with AKI, because of the 
belief that convective clearance might benefit patients 
by better removal of toxic inflammatory solutes, which 
are in the middle molecular range. Despite such beliefs, 
no studies have shown a convincing and sustained effect 
of continuous hemofiltration technique on circulating 
cytokine levels compared with continuous hemodialysis. 
Moreover, a recent meta-analysis [69] showed no effect 
of continuous hemofiltration on mortality and dialysis 
dependence in AKI patients compared with hemodialy-
sis; in contrast, continuous hemofiltration appeared to 
shorten time to filter failure by 7 h. Thus, there is no level 
1 evidence to guide clinicians in their choice of technique 
during CRRT, and there is some lower-level suggestive 
evidence that diffusion (hemodialysis) may be gentler on 
the filter and may therefore prolong circuit life.
Less common techniques: slow low‑efficiency dialysis 
(SLED)
As given in Table  3, SLED, a relatively new “hybrid” 
technology combining the properties from both IHD 
and CRRT, is a special form of intermittent dialysis with 
low dialysate and blood flow rates and prolonged dura-
tion. A recent meta-analysis [70], including 7 RCTs and 
10 observational studies, reported that there was a mild 
trend toward improved survival in favor of SLED-treated 
patients with AKI (RR 0.86; 95% CI 0.74–1.00), although 
the evidence was weak because of a lack of significant dif-
ferences when RCTs were considered separately. None-
theless, there might be some potential advantages of 
SLED in general. First, SLED might lead to more rapid 
mobilization of patients and perhaps lead to shorter 
ICU stays and more rapid convalescence. Second, short 
and flexible duration of therapy might to some extent 
decrease the complications of RRT such as bleeding, 
hypotension, fluid overload as seen in other therapies like 
IHD. Third, a shorter duration of RRT might be associ-
ated with a lower rate of biofilm formation and circuit 
contamination.
Peritoneal dialysis
In the past, PD has not been considered as the first 
choice of RRT for AKI in adults because of the low effi-
ciency of solute clearance. However, there are now sev-
eral RCTs focusing on continuous PD for AKI patients 
compared with IHD, CRRT or SLED, reporting similar 
mortality and kidney recovery [71–73]. A recent pooled 
Table 3 Characteristics of CRRT, SLED and IHD
CRRT continuous renal replacement therapy, SLED sustained low-efficiency 
dialysis, IHD intermittent hemodialysis, CVVH continuous venovenous 
hemofiltration, CVVHDF continuous venovenous hemodiafiltration, CVVHD 
continuous venovenous hemodialysis, SLED-f sustained low-efficiency 
hemodiafiltration, IHD-f intermittent hemodiafiltration
CRRT SLED IHD
Modality CVVH/CVVHDF/
CVVHD
SLED/SLED‑f IHD/IHD‑f
Duration per 
session
24 h 6–12 h 4 h
Frequency 24 h/day 3–6/week 3/week
Blood flow  
(ml/min)
100–200 100–200 250–350
Dialysate dose 20–25 ml/kg/h 100–300 ml/min 500–800 ml/min
Hemodynamic 
status
Stable Possible stable Unstable
Volume control +++ ++ +
Heparin dose High Moderate Low
Fig. 5 Schematic illustration of continuous hemofiltration, hemodialysis and hemodiafiltration circuits
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meta-analysis also reported no difference in mortality 
between PD and extracorporeal RRTs [74]. Due to the 
lack of widespread use in developed countries and lim-
ited evidence, there is a need for better quality evidence 
in this important area.
Conclusions
CRRT remains the most popular modality of RRT in 
ICU patients with severe AKI, but there is no evidence to 
support any benefits on mortality compared with other 
RRT modalities. However, compared with IHD, some 
large observational studies have reported higher rates of 
kidney recovery in CRRT-treated AKI patients, suggest-
ing that IHD may adversely impact the process of renal 
recovery. The effect of SLED and PD on AKI needs to be 
better assessed and confirmed by high-quality studies. 
In clinical practice, individual-adjusted therapy should 
be recommended rather than focusing on any particu-
lar form of RRT. In this regard, there is a consensus that 
CRRT might be the optimal treatment for AKI patients 
with unstable hemodynamics or severe fluid overload. 
In contrast, IHD might be a reasonable choice when 
patients become stable or have left the ICU. The use of 
SLED may represent a reasonable alternative to CRRT in 
the ICU and a reasonable alternative to IHD outside the 
ICU.
Positive fluid balance as an indication for RRT
Fluid administration is a key component of resuscitation 
strategies in the management of patients with hypoten-
sion and shock and can be envisioned in separate phases, 
permitting a clearer delineation of the therapeutic need 
[75]. In most instances, immediate resuscitation requires 
administration of adequate volumes of fluid and contin-
ued assessment and monitoring to determine improved 
hemodynamics and tissue perfusion [76]. Based on the 
surviving sepsis guidelines, the goals of therapy have 
included initial fluid boluses of 30  ml/kg followed by 
maintenance fluids to maintain adequate cardiac output 
and tissue perfusion. While several strategies have been 
tested for the fluid administration, it is unclear whether 
any approach is superior [77]. There are no criteria for 
deescalating fluid therapy and in practice fluids are often 
continued particularly when there is hemodynamic insta-
bility. A net result is accumulation of fluid over the course 
of therapy with resulting fluid overload. Several factors 
contribute to the fluid retention including an increased 
vascular permeability, alterations in the glycocalyx 
matrix and leakage of plasma proteins into the inter-
stitial space with decreased oncotic pressure [78]. The 
process is further complicated if the kidney is affected 
by the underlying disease process or secondarily injured 
from the hypotension or nephrotoxic agents. The level of 
renal impairment may not be as evident as the SCr values 
are diluted by the fluid accumulation [11]. The resulting 
fluid overload, with thresholds of 10% excess from the 
admission weight, is associated with an incremental risk 
of mortality in patients with and without AKI [79]. Fluid 
overloaded patients have an increased risk of AKI [80, 
81], and there is reduced renal recovery from AKI [82]. 
Several studies have shown that both the magnitude and 
persistence of fluid overload are associated with worse 
outcomes, suggesting that prevention and correction of 
fluid accumulation are modifiable risk factors to improve 
survival. Removal of fluid and optimization of fluid bal-
ance lower the risk and improve outcomes [80].
As the underlying disease process improves eventu-
ally the accumulated fluid is removed mainly through 
diuresis [83]. However, if the course is complicated by 
additional hits, fluid retention continues to accrue with 
deleterious consequences [84]. Salinas et  al. [85] have 
shown that a computerized decision support for fluid 
management in burn patients led to reduce amount of 
fluid being used, lower fluid accumulation and improved 
survival. Similarly achieving negative fluid balance in 
patients with acute lung injury was associated with bet-
ter outcomes [86]. It is thus imperative that fluid manage-
ment strategies include a de-escalation phase to optimize 
fluid balance [87]. We have utilized CRRT to achieve 
and maintain fluid balance in these circumstances keep-
ing hemodynamic balance in place [88–90]. We target 
an hourly fluid balance to maintain tissue perfusion and 
adjust volume administration and removal coupled with 
vasopressor and inotropic support for a comprehensive 
organ support. The CRRT system reduces the burden 
on the kidney, avoids the deleterious effects of aggres-
sive diuretic use and permits fluid optimization by cre-
ating space for all the nutrition and drug delivery that is 
required. This fluid regulatory role of CRRT improves 
the time to weaning from ventilation and avoids the 
complications of prolonged fluid retention. Adjunctive 
CRRT therapy is a viable option to manage critically ill 
patients and should be considered for patients who have 
fluid accumulation particularly when renal function is 
impaired.
IHD for shocked patients
After more than 20 years of an intense debate, the con-
troversy still persists regarding the place of continuous 
or intermittent RRT (i.e., CRRT or IHD) to treat acute 
renal failure in ICU. The purpose of this controversy 
concerns mainly the tolerance of intermittent therapy 
for shocked patients and the associate complications 
like delayed renal recovery or death. For all that, KDIGO 
agree that the two methods may be used in ICU to treat 
AKI “as complementary therapies” [91]. The matter of 
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debate remains for patients with hemodynamic instabil-
ity requiring RRT. In this setting, international guidelines 
recommend the use of continuous therapy (KDIGO), 
while French guidelines consider the two methods equal 
[92].
Numerous old studies compared both methods. Most 
of them were non-randomized, retrospective trials 
and reported conflicting results. Many methodological 
biases preclude conclusive information. Nowadays, we 
know that hemodynamic tolerance can be significantly 
improved by using specific settings in IHD for critically 
ill patients [93]. These settings include a tailored net 
ultrafiltration amount with respect to the fluid balance, 
some dialysate modification (i.e., enriched sodium con-
centration and mild hypothermia) and duration above 
4 h. Schortgen et al. [93] reported an improved hemody-
namic tolerance using these settings. These results were 
confirmed in prospective randomized studies including 
patients with shock [64]. Keeping in mind that the num-
ber of patients randomized with shock is quite modest, 
no prospective study reports any hemodynamic adverse 
event using intermittent modality. To date, six prospec-
tive randomized studies have been published, some of 
them including shocked patients. Except one with group 
imbalance, all other did not find any significant differ-
ence of mortality of renal recovery comparing intermit-
tent or continuous modality. These results are supported 
by several meta-analysis pooling the above-mentioned 
studies. Of note, continuous methods are not devoid of 
hemodynamic adverse events. In the RENAL study [94] 
comparing two doses of dialysis in ICU patients, the low-
dose group experienced not less than 24% of arrhythmia, 
leading to hemodynamic instability.
Regarding renal recovery, the analysis is quite more dif-
ficult. There is no consensual definition and the evalua-
tion relies usually on ICU or hospital discharge, which 
may be relatively short. Usually, the definition is based 
on RRT dependency. However, delayed renal recovery 
and death represent two competitive risks. While pro-
spective comparative studies are negative with respect 
to renal recovery, retrospective studies report higher 
renal dependency with intermittent modality. The non-
randomized design leads to imbalance between groups. 
Severe patients with high mortality are treated with 
CRRT, while IHD is dedicated to less severe patients. 
Thus, the risk to become dialysis dependent is increased 
in the group with the lowest mortality (i.e., IHD group).
Finally, what may best explain the discrepancy between 
the two modalities is the practice across the world. 
Based on a questionnaire, it appears that IHD is usually 
prescribed by nephrologists and monitored by dialysis 
nurses, while CRRT is under the authority and the moni-
toring of intensive care team [95]. With this organization 
of care, we can guess that the availability of IHD as well as 
the experience of ICU team with this modality is unsuit-
able for most ICU patients whatever the quality of IHD.
To conclude, we could combine the two recent guide-
lines [91, 94] in the same sentence: “Continuous and 
intermittent RRT techniques can be used equally, as 
complementary therapies, taking into account their avail-
ability and the experience of the team.”
HCO membranes in sepsis
Introduction
The release of pro- and anti-inflammatory cytokines 
from activated immune cells is a key feature of inflamma-
tion and is vital for pathogen clearance and attenuation/
recovery of tissue damage. Uncontrolled or imbalanced 
release of such cytokines can, however, be harmful. In 
fact, an overwhelming inflammatory response to surgery, 
trauma and infections is a major cause of organ dam-
age and mortality in critically ill patients [96]. Cytokine 
removal by extracorporeal blood purification has been 
suggested a potential therapeutic option to improve out-
comes in septic patients [97]. Such blood purification 
techniques include high-volume hemofiltration, plasma 
adsorption, plasma filtration, combined plasma filtration 
and adsorption and high cutoff (HCO) hemofiltration 
and hemodialysis. Of these techniques, HCO hemofil-
tration/hemodialysis appears particularly efficient to 
achieve high cytokine clearance [98]. We describe the 
biochemical effects of this technique and its potential 
clinical effects.
HCO membrane characteristics
Membrane cutoff is defined by the molecular weight (in 
kDa) of molecules with a sieving coefficient (SC) of 10% 
across the membrane. Conventional membranes have 
a cutoff of approximately 30  kDa, i.e., only about 10% 
of middle molecular weight cytokines (e.g., TNF-alfa, 
26  kDa) would theoretically pass such filters. In reality, 
however, the SC is significantly lower, which means that 
cytokine removal during standard RRT is negligible [98]. 
In contrast, HCO membranes have a clinical cutoff of 
60–100 kDa and a pore size approximately twice as large 
as that in conventional membranes. A systematic review 
of ex  vivo studies concluded that HCO hemofiltration 
achieved greater median clearance of IL-1β (1.4-fold), 
IL-6 (tenfold) and TNF-α (60-fold) than standard hemo-
filtration. Furthermore, with the exception of TNF-α, 
HCO hemofiltration greatly enhanced cytokine clearance 
in animal and human experiments [99, 100].
Cytokine clearance is dictated not only by molecu-
lar weight and membrane characteristics but also, as 
confirmed by previous ex  vivo studies, by the intensity 
and mechanism (diffusion versus convection) of solute 
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clearance [101, 102]. Compared to hemodialysis (diffu-
sive clearance), higher clearance of IL-1ra, IL-1β, IL-6, 
IL-8 and TNF-α is achieved with hemofiltration (convec-
tive clearance). Increased cytokine clearance with higher 
ultrafiltrate/dialysate flow rate can also be expected. In 
addition to improved cytokine removal during hemofil-
tration, the concomitant loss of essential proteins, such as 
albumin, has been a concern. In fact, albumin clearance 
can amount to 10  ml/min during hemofiltration [102]. 
Such albumin losses can, however, easily be replaced by 
infusion of albumin solutions.
Cytokine removal via HCO membranes: clinical effects
So far, only a few small studies have been explored the 
clinical utility of HCO membranes in septic patients 
(Table  4). Cytokine clearance and illness severity were 
quantified in 24 patients with septic AKI randomized 
to continuous venovenous hemofiltration (CVVH) or 
continuous venovenous hemodialysis (CVVHD) [103]. 
Additionally, the clinical and biochemical effects of 
ultrafiltration rate and dialysate flow rate were explored. 
Compared to CVVHD, greater IL-6 clearance was 
achieved with CVVH. Irrespective of modality, higher 
flow rates led to greater IL-6 and IL-1ra clearance. 
Overall, APACHE II and multiorgan dysfunction syn-
drome score decreased after 24  h, however, without a 
detectable difference between the CVVH and CVVHD 
groups.
In a randomized controlled trial, 30 patients with septic 
AKI were allocated to HCO CVVH (n = 20; membrane 
cutoff 60  kDa) or conventional CVVH (n  =  10; mem-
brane cutoff 30  kDa) using post-filter replacement vol-
umes of 2.5 L/h in both groups [9]. At 48  h, decreased 
plasma levels of IL-6, IL-1ra and CRP was observed 
in the HCO group but not in the conventional group. 
Furthermore, patients treated with HCO CVVH had sig-
nificantly lower SAPS II score and vasopressor require-
ments after 48 h suggesting a clinical benefit of cytokine 
removal.
A phase 1 crossover trial compared a HCO filter with a 
conventional filter during IHD in 10 septic AKI patients 
[104]. A greater decrease in plasma IL-6, IL-8 and IL-10 
was observed after 4  h of HCO-IHD, whereas no dif-
ference in IL-18, urea and albumin removal was found. 
Interestingly, there was a trend toward increased MAP 
and reduced vasopressor requirements after a 4-hour 
treatment with HCO-IHD.
A likely link between sepsis-induced release of inflam-
matory mediators (e.g., cytokines), activation of apop-
totic pathways and organ injury has been proposed [105, 
106]. Whether cytokine removal mitigates this response 
and translates into clinical benefits should therefore 
be explored. Recently, a randomized controlled trial 
(ClinicalTrials.gov Identifier: NCT00912184) completed 
recruitment of 76 patients with the aim to compare vaso-
pressor requirements during HCO (100  kDa) CVVH 
or standard (30  kDa) CVVH. In a subset of patients 
enrolled in that trial, pro-apoptotic plasma activity was 
compared between the two groups [107]. At baseline, 
apoptotic activity in these AKI patients’ plasma was 
evident by DNA fragmentation, caspase-3 activity and 
phosphatidylserine exposure on cell membranes. After 
24  h, significantly less phosphatidylserine exposure was 
demonstrated in the HCO group, whereas no difference 
in DNA fragmentation or caspase-3 activity was found. 
Over a 3-day assessment period, no robust changes in 
apoptotic activity were seen in either group. Based on 
these findings, the effect of cytokine removal on apopto-
sis and organ injury remains uncertain and needs to be 
further explored.
Table 4 Cytokine clearance, albumin clearance and clinical effects of renal replacement therapy using high cutoff mem‑
branes
RRT renal replacement therapy, Qf ultrafiltration rate, Qd dialysate flow rate, CVVH continuous venovenous hemofiltration, CVVHD continuous venovenous 
hemodialysis, IHD intermittent hemodialysis, APACHE acute physiology and chronic health evaluation, MODS multiorgan dysfunction syndrome
a Estimated in vivo membrane cutoff
First author, 
year
N RRT modal‑
ity
Qf or Qd (l/h) Cutoffa 
(kDa)
Cytokine clearance Albumin clearance Clinical effects
Morgera 
et al. [103]
24 CVVH versus 
CVVHD
Qf 1 versus 2.5
Qd 1 versus 2.5
60 Greater IL‑1ra clearance 
with CVVH. Increased 
Qf or Qd increased IL‑6 
and IL‑1ra clearance
Highest with CVVH 
2.5 l/h
Overall decrease in APACHE II and 
MODS scores. No difference 
between groups
Morgera 
[235]
30 CVVH Qf 2.5 30 versus 
60
Greater IL‑6 and IL‑1ra 
clearance with 60 kDa‑
filter
Plasma albumin levels 
not affected by filter 
cutoff
Reduced noradrenaline require‑
ments with 60 kDa‑filter
Haase et al. 
[104]
10 IHD Qd 18 20 versus 
60
Greater IL‑6, IL‑8 and 
IL‑10 clearance with 
60 kDa‑filter
Plasma albumin levels 
not affected by filter 
cutoff
Trend toward increased mean 
arterial pressure and reduced 
vasopressor requirements with 
60 kDa‑filter
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Conclusion
Blood purification via HCO filters has been safely used in 
septic AKI patients to effectively remove cytokines from 
the circulation. Hemofiltration increases cytokine clear-
ance more than hemodialysis but also leads to greater 
albumin losses. Clinical benefits of blood purification via 
HCO filters in septic patients have been suggested but 
need to be determined in larger trials.
Vascular access sites for acute renal replacement in ICUs
The treatment of severe AKI with RRT often requires 
to obtain a central venous access. Non-tunneled, non-
cuffed, temporary, relatively large central venous cath-
eters (CVC) are used for this purpose in the critical care 
environment. A good vascular access site should reduce 
the risk of immediate mechanical complications during 
insertion, limit the risk of late infectious or thrombotic 
complications once the catheter is inserted and provide 
an adequate flow to perform RRT during the course of 
AKI.
The subclavian veins should not be used when possi-
ble, as there is an increased risk of thrombosis when large 
catheters are inserted in a small vein. The right jugular 
vein has been historically considered the gold stand-
ard for vascular access in this context and the femoral 
vein should be avoided, or considered in the last resort 
for emergent situations. This poor reputation was based 
on a seminal study in which the risk of catheter-related 
bloodstream infection increased exponentially after one 
week among patients requiring acute hemodialysis [108]. 
Of note, this study was not randomized and performed 
outside the intensive care setting. Patients in the medi-
cal wards, however, differ in many respects from critically 
ill patients, raising the question of whether these recom-
mendations can be extrapolated to critically ill patients.
To investigate which vascular access was best for acute 
RRT in the ICU, our group conducted the first large rand-
omized multicenter study comparing internal jugular and 
femoral vein catheterization in the ICU. The CATHEDIA 
study [109–112] was aimed to compare the jugular and 
femoral sites for:
1. the risk of catheter infection
2. the risk of mechanical complications
3. the risk of thrombosis
4. the risk of catheter dysfunction and the quality of 
RRT.
In addition, the epidemiology of the infectious risk 
according to the type of RRT (e.g., IHD versus continu-
ous venovenous hemodiafiltration) and the case of the 
second catheter were investigated. The key findings of the 
CATHEDIA trial are summarized in Table 5.
Overall, the results of the CATHEDIA study suggest 
that the best vascular access choice may depend on sev-
eral factors independent from the patient such as the 
physician experience and the availability of ultrasound 
guidance. In the large majority of cases, the femoral and 
jugular accesses will carry a similar risk of complications 
and similar dialysis quality. There are some exceptions 
however, in which the intensivist may want to prefer 
one site over the other: The right internal jugular inser-
tion site may be preferred to deliver the best RRT dose 
if the prescribed blood blow is higher than 200 ml/min, 
the femoral site should be avoided if the BMI > 28, if the 
femoral site is contaminated or if the patient is ambula-
tory; the jugular site should be avoided in case of trache-
ostomy or if the site is contaminated.
The management of dialysis catheter represents an 
important factor for the success of ICU RRT. The type 
of catheter and catheterization procedures, especially 
in the insertion site and catheter maintenance (flushes, 
locks), affects the quality of RRT and the risk of catheter 
dysfunction. The epidemiology of the catheters used for 
RRT is very similar to the more studied epidemiology 
of the catheters used for administrating drugs, although 
the rate of thrombosis seems lower in RRT CVC, pos-
sibly due to anticoagulation. Therefore, the same bun-
dle of care needs to be implemented to limit the risk of 
potentially severe complications. This includes infection 
control procedures and checklists, learning and teach-
ing safer vascular access by the use of ultrasound-guided 
insertion (real time), removing unnecessary catheters and 
optimal skin disinfection and CVC care with alcoholic 2% 
chlorhexidine or alcoholic povidone–iodine in case of 
contraindication to chlorhexidine use. Of note, catheters 
should not be removed after a predetermined amount of 
time to prevent the risk of infection [109].
During the last decade, new evidence-based data 
regarding vascular access have emerged. We hope these 
findings will inform intensivists and contribute to avoid 
potentially preventable healthcare-associated complica-
tions while providing better quality of care to this severe 
subset of the ICU population.
Acute renal failure as a witness of systemic diseases
In 10–20% of patients with ARF, not related to obstruc-
tion or hypovolemia, a systemic disease is the cause 
of AKI, affecting mainly small vessels and glomeruli. 
Usually, an associated acute tubular necrosis (ATN) 
is present. Macro-proteinuria, albuminuria, hematu-
ria and extrarenal signs, affecting skin, joints, neurons 
or lung, should alert the clinician that the clinical pres-
entation is quite different from the usual AKI seen in 
ICU, that is ATN. The main diagnoses are rapidly pro-
gressive GN (RPGN), thrombotic microangiopathies 
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(TMA), cholesterol crystal embolism and catastrophic 
antiphospholipid syndrome [36]. For RPGN, an extensive 
immunologic screening, looking for ANCA, anti-GBM 
antibodies, ANA and anti-DNA antibodies, cryoglobu-
linemia and complements C3 and C4, is needed. A renal 
biopsy may be required [36] to determine the appropri-
ate treatment, which should be started rapidly. For TMA, 
anemia, reticulocytes, schistocytes, increase in LDH, 
low haptoglobin levels and low platelet count are found. 
The diagnostic screening includes stool culture to detect 
Shiga-toxin-producing E coli, PCR analysis for Shiga-
toxin detection, plasma ADAMTS-13 determination, as 
well as alternate pathway of complement exploration (C3, 
C4, facteur H, I and MCP, factor B) and antiphospholipid 
antibodies.
RPGN are characterized by an acute glomerular ext-
racapillary proliferation and fibrin deposition, combined 
with a rapidly progressive renal failure. By immunofluo-
rescence, different patterns are observed: linear deposi-
tion of IgG along the glomerular basement membrane in 
Goodpasture syndrome, where pulmonary hemorrhage 
is life-threatening; granular deposition of IgG and C3 in 
lupus disease, cryoglobulinemia, and endocarditis; IgA 
deposition in Henoch–Schonlein disease; and no signifi-
cant immune deposition in ANCA-associated vasculitis. 
An aggressive treatment is needed, with high doses of 
steroids, plasma exchanges and cyclophosphamide, to 
prevent life-threatening complications and to improve 
renal prognosis. The poorest renal and patient prognosis 
is associated with a SCr at entry greater than 500 µmol/l, 
a need for hemodialysis and crescentic lesions in 100% 
of the glomeruli. In ANCA-associated vasculitis, plasma 
exchanges were shown to improve renal function and 
renal prognosis but not patient survival when compared 
to high doses of steroids [113]. More recently, rituximab 
was reported to give similar results when compared to 
cyclophosphamide in mild-to-moderate forms of the 
disease.
In TMA with acute renal failure, different mecha-
nisms and diseases are possible: Shiga-toxin-induced 
hemolytic uremic syndrome (HUS), atypical HUS, more 
rarely thrombotic thrombocytopenic purpura (TTP) 
with low ADAMTS-13 activity. It may also be related to 
drug-related TMA (bevacizumab, calcineurin inhibi-
tors, gemcitabine, mitomycin C), systemic infection, sys-
temic cancer, severe preeclampsia and HELLP syndrome, 
malignant hypertension, autoimmune disease (systemic 
sclerosis, lupus, CAPS) or hematopoietic stem cell or 
organ transplantation. The differential diagnosis is some-
times difficult in adults. Clinical signs are numerous, 
including renal failure, hypertension, abdominal pain and 
diarrhea, headaches and seizures, myocardial infarction 
and cardiomyopathy. When performed, the renal biopsy 
shows microthrombotic lesions in glomerular capil-
lary and/or small arterioles, double contour pattern, and 
in the most severe forms, areas of cortical necrosis. In 
most of the cases, plasma therapy has to be started rap-
idly, usually with 60  ml/kg/day plasma exchanges until 
normalization of platelets count. If TTP is diagnosed, 
rituximab should be considered in the absence of rapid 
normalization of platelet count. If complement-medi-
ated HUS is diagnosed, eculizumab should be admin-
istered. In cases of Shiga-toxin-induced HUS, there is 
no evidence that plasma exchanges, steroids or eculi-
zumab are useful [114], although some case reports sug-
gest that eculizumab should be given in the most severe 
Table 5 Main results of the CATHEDIA trial
Refs. Design Outcome Highlights
[2] RCT, parallel Catheter infection The risk of catheter infection inserted in FEM and JUG is similar
RCT, parallel Catheter infection JUG site may be preferred in obese patients
RCT, parallel Thrombosis The risk of thrombosis is similar in FEM and JUG is similar
RCT, parallel Severe mechanical injury Without ultrasound guidance, FEM is safer than JUG
[3] RCT, parallel Catheter dysfunction The risk to dysfunction is similar in FEM and JUG is similar
Cohort Catheter dysfunction Right side of the body should be preferred for JUG
RCT, cluster Dialysis quality Urea Reduction Ratio is similar in FEM and JUG
Cohort Dialysis quality For blood flow >200 ml/min, jugular is better
Cohort Dialysis quality Length for FEM catheter should be >25 cm
[4] Cohort Catheter colonization The risk of infection does not increase overtime with hemodialysis
Cohort Catheter colonization The risk of infection increases overtime with hemodiafiltration
[5] RCT, crossover Catheter infection The risk of catheter infection inserted in FEM and JUG is similar
RCT, crossover Dialysis quality Urea Reduction Ratio is similar in FEM and JUG
RCT, crossover Catheter dysfunction The risk to dysfunction is similar in FEM and JUG is similar
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forms [115]. In any case, it is important to strictly control 
hypertension, since hypertension per se has a deleterious 
effect on the microvascular lesions and plays an aggravat-
ing role in HUS.
In conclusion, ARF in ICU is not always related to 
acute tubular lesions. It can be also related to systemic 
diseases that have to be recognized rapidly since specific 
treatments are available that change both the renal and 
patient prognoses.
Liver and kidney: a relationship
Definitions
Traditionally all patients with renal dysfunction and liver 
disease were classified as having the dreaded diagnosis 
of hepatorenal failure and labeled with a dismal progno-
sis and not offered further therapeutic interventions—
thankfully things have and continue to change and we 
have become more elegant in both our descriptions and 
management of patients with renal dysfunction.
The new definitions as described by Wong and Angeli, 
respectively [116, 117], clearly recognize the importance 
of the utilizing RIFLE and ADQI definitions in delin-
eating hepatorenal failure (HRF) types 1 and 2. Acute 
kidney injury (AKI) in cirrhosis is described as a rise in 
creatinine of >50% from baseline or a rise of >26.5 µmol/l 
in 48  h, with type 1 HRF being a specific form of AKI. 
Chronic kidney disease (CKD) is defined as a glomeru-
lar filtration rate (GFR) of <60  ml/min for greater than 
3 months and specifies that HRF type 2 is a specific form 
of CKD. A further category of acute of chronic kidney 
disease (AoCRF) is a rise in creatinine of >50% from 
baseline or by greater than 26.5 µmol/l in less than 48 h 
in a patient with a GFR  <  60  ml/min for greater than 
3 months.
Pathophysiology
The classic description for the development of HRF is 
based on the development of arterial vasodilation and 
splanchnic vasodilation and effective central blood vol-
ume depletion. This results in activation of vasocon-
strictor systems (angiotensin, aldosterone), altered 
renal autoregulation, intra-renal vasoconstriction and 
sodium retention [118]. Contributory factors in the 
CKD of cirrhotics are parenchymal renal disease, dia-
betic, hypertensive and immune-mediated pathologies 
(Ref ). Large-volume ascites and associated intra-abdom-
inal hypertension may decrease renal perfusion pressure 
result in a further insult (AoCRF). In a subgroup of cir-
rhotics, pulmonary venous hypertension results in cen-
tral volume overload and elevated right-sided pressures 
may also contribute to both CRF and AoCRF (refs). Pul-
monary arterial hypertension becomes significant when 
pressure volume overload develops.
Diagnostic difficulties
One of the concerns of a cutoff creatinine level to define 
AKI in cirrhosis is the failure of creatinine to equate to 
GFR. Correlation between eGFR and gold-standard 
GFR (EDTA or iohexol) is poor due to a combination 
of decreased creatine production and decreased mus-
cle mass. Recent studies demonstrated that only 30% of 
patients with a gold-standard GFR of <60  ml/min were 
identified using calculated formulae. Normal creatinine 
in a cirrhotic was likely being in the region of 65 µmol/l 
as compared to the standard normal range [119].
The diagnostic criteria for HRF within the AKI model 
are that of diagnosis of AKI, no response to intervention 
over 48 h, absence of shock, no recent use of nephrotox-
ins, contrast media and no macroscopic signs of paren-
chymal disease (no proteinuria of >500  mg/day, no 
microhematuria and normal renal ultrasound). Using 
these standards HRF is likely to a rare diagnosis
Various biomarkers were examined in a recent study 
by Belcher et  al. [120], NGAL, IL-18, KIM-1, L-FABP, 
proteinuria and urinary sodium all had diagnostic util-
ity to separate pre-renal, HRF and acute tubular necrosis. 
Area under the curve was optimal at >0.7 for NGAL and 
IL-18 and proteinuria but only 0.56 for urinary sodium. 
The presence of low-level proteinuria (PCR > 30) has also 
been shown to be highly predictive of development of 
AKI [119].
The underling etiology of AKI has been shown by two 
studies to clearly impact on prognosis; the worst 3-month 
survival being seen for HRF (15%), while hypovolemia 
was 46% and infection related 31% [121] and similar data 
seen in [122]
Management
Management of HRF has been described elegantly in the 
paper of Angeli et  al.; stage 1 AKI should result in the 
removal of putative nephrotoxins, treatment of hypov-
olemia and sepsis, hyponatremia should always result in 
diuretic withdrawal. If AKI progresses to stages 2 and 3, 
diuretics are discontinued if this has not already occurred, 
and albumin should be administered at 1 g/kg for 2 days. 
If the patient then meets criteria for HRF, vasoconstric-
tor therapy should be administered. Volume should be 
administered if the patient is though deplete—a simple 
statement and a complex clinical decision. Clinicians are 
poor at delineating volume status, and the use of echocar-
diography should be considered to define volume status 
and avoid volume overload or excessive fluid adminis-
tration, both of which are as detrimental as volume 
depletion.
Instituting vasoconstrictor therapy only at stages 2 and 
3 may be questioned given the work of Krag et al. [123] 
showing beneficial effects on eGFR, renal blood flow, 
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urinary sodium clearance and water clearance when 
administered to cirrhotics with ascites but no AKI. These 
data along with that of greater chance of therapeutic 
response being seen with lower creatinine levels would 
argue for earlier consideration of vasoconstrictors, albeit 
it recognizing the potential side effects of potent vaso-
constrictor. Albumin is proposed for all patients with 
AKI and has benefit in SBP sepsis, although this effect 
has not been seen in other septic etiologies [124].
The data to support the use of vasoconstrictor and 
albumin therapy is supported with regard to reversal of 
HRF by a Cochrane review, and data from the Terlipres-
sin Study Group showed reversal of HRF is seen to be 
affected by treatment group, while survival is related to 
etiology of alcoholic hepatitis, MELD score and serum 
creatinine [125]. The choice of vasoconstrictor therapy 
is normally that of terlipressin, with a starting dose of 
0.5 mg 6 hourly and rising to 1 mg 6 hourly. Duvoux et al. 
showed a response to norepinephrine, and a RCT dem-
onstrated equivalence when comparing norepinephrine 
and terlipressin, with the predictors of outcome being 
creatinine clearance at enrollment, mean arterial pres-
sure and renin level [126]. Glucocorticoid therapy with 
or without N-acetylcysteine (NAC) for the treatment of 
alcoholic hepatitis was associated with decreased HRF in 
the NAC limb [127].
Other therapeutic options should consider the detri-
mental effect of elevated intra-abdominal pressure (IAP) 
in decreasing renal perfusion pressure and contributing 
to AKI. Treatments may be to increase mean arterial 
pressure or low-volume paracentesis to decrease intra-
abdominal pressure. Data from Umgelter et  al. [128] 
showed a decrease in creatinine following low-volume 
paracentesis. When draining ascites caution should 
be exercised to prevent further central hypovolemia 
with associated with a decrease in IAP and subsequent 
splanchnic vasodilation, this can be achieved by either 
albumin therapy or terlipressin [129].
In patients who do not respond to vasoconstrictor ther-
apy, consideration should be given to undertaking renal 
replacement therapy (RRT). Early institution of RRT has 
been suggested to improve outcome and in cirrhosis this 
is especially pertinent given the failure of creatinine to 
reflect GFR. Furthermore, early RRT allows control of 
serum sodium and avoidance of critical hyponatremia 
which may, along with hyperammonemia, contribute to 
significant deterioration in conscious level (refs).
Outcome
Development of AKI or AoCKD is clearly associated 
with increased mortality, and the CLIF organ failure 
score includes creatinine along with bilirubin, coagula-
tion, circulatory and respiratory parameters [130]. The 
subsequently refined CLIF-C score incorporates WBC 
and age [131]. Predictors of mortality (30 day) in cirrhot-
ics with AKI have been shown to be mean arterial pres-
sure, severity of liver disease as measured by MELD score, 
spontaneous bacterial peritonitis (SBP) and number of 
organs failing [132].
ARF as a witness of cardiac arrest
Acute heart failure patients have a high risk of developing 
renal failure under the type 2 cardiorenal syndrome (i.e., 
acute heart failure affecting renal function). Furthermore, 
acute cardiorenal syndrome has been associated with 
poor outcome in acute heart failure patients. Systemic 
hemodynamic has long been thought to play a central 
role in the worsening renal function associated with acute 
decompensated heart failure (ADHF) [133]. Historical 
physiological studies have emphasized the role of venous 
congestion. Increasing central venous pressure while 
maintaining arterial pressure is associated with a drop of 
renal blood flow, drop of GFR and anti-natriuresis [134] 
(Fig. 6). More recently, CVP was shown to be associated 
with a risk of WRF in ADHF patients, while cardiac index 
or arterial pressure was not. Legrand et al. also observed 
that CVP was associated with a risk of worsening renal 
function in patients with severe sepsis, especially when 
CVP rose above 12  mmHg [135]. Herrler et  al. further 
highlighted the role of increase compartmental pressure 
in the kidney in showing that capsular removal induced 
pressure relief and prevented functional and structural 
renal impairment after renal ischemia–reperfusion [54]. 
The impact of venous congestion the kidney can, how-
ever, lie way beyond the alteration of renal function 
(detected as a decrease in eGFR or a rise in serum cre-
atinine). In this line, because it is the easiest and most 
available biomarker of renal injury, drop of GFR may only 
represent the tip of the iceberg of renal consequences of 
venous congestion. The use of recently developed bio-
markers of renal injury (especially tubular injury) has 
allowed to identify some degree of renal injury in heart 
failure. However, renal injury biomarkers have failed in 
many studies to identify patients who later had a drop 
of GFR due to the complex relationship between renal 
injury and glomerular function in these patients [133]. 
Transient venous congestion has also been shown to 
alter the microcirculation and induce endothelial injury 
and local inflammatory response [136]. Hypervolemia 
was shown to degrade the glycocalyx at the surface of the 
endothelial layer, an essential compound of the micro-
vascular function influencing permeability. Release of 
natriuretic peptide might play a role in this degradation 
since infusion of ANP in animals degraded the glycoca-
lyx layer independently of changes of intravascular vol-
ume. A key component of the venous congestion in acute 
Page 20 of 40Bellomo et al. Ann. Intensive Care  (2017) 7:49 
heart failure patients appears to be the excess of intravas-
cular volume, which has been found to range from +9.5 
to +107% of normal value in ADHF on admission [137]. 
Reasons for intravascular volume result from progres-
sive retention of water and sodium due to anti-natriure-
sis in such patients. Several factors contribute to intense 
sodium reabsorption ADHF patients. Among them, 
decrease in renal blood flow contributes to increase in 
sodium reabsorption at the proximal tubules level. Main-
tenance of GFR lies on increase of filtration fraction with 
hemoconcentration in the efferent arteriole and peri-
tubular capillaries. Increase in protein concentration in 
peritubular capillaries will then promote passive sodium 
and water reabsorption in proximal tubules. Activation of 
the renine–angiotensine–aldosterone system is another 
factor promoting sodium tubular reabsorption. Interest-
ingly, use of loop diuretics can promote RAAS activation 
through decrease in chloride concentration in cells of the 
macula densa leading to renin secretion.
Therapeutic strategies to control sodium and fluid balance 
in ADHF aim at limiting venous congestion and renal injury. 
In this line, some degree of hemoconcentration with rise in 
hematocrit and slight decrease in GFR has been associated 
with better outcome in ADHF [138]. Furthermore, failure 
to increase diuresis and to control fluid balance using loop 
diuretics has been associated with poorer outcome in these 
patients. Interestingly, GFR does not appear to be a predic-
tive factor to loop diuretics resistance, suggesting that altered 
intra-renal hemodynamics and tubular dysfunction might be 
involved. Association of diuretics can overcome this resist-
ance to diuretics. Thiazide diuretics inhibit distal tubules 
sodium reabsorption. Acetazolamide through proximal 
tubules sodium reabsoption inhibition and mineralocorti-
coids receptors inhibitors are also to be considered although 
data in ADHF patients are lacking. Finally, interest of ultra-
filtration has long been emphasized in these patients, but 
review of its use is out of the scope of this manuscript. Future 
studies should better determine whether fluid control strate-
gies may protect the kidney form injury and failure in ADHF 
and may improve global outcome in these patients in modu-
lating injury pathways through organ cross talks.
Acute renal failure as a witness of abdominal hypertension
A recent meta-analysis confirmed that intra-abdominal 
hypertension (IAH), defined as a sustained increase in 
intra-abdominal pressure (IAP) above 12  mmHg, and 
abdominal compartment syndrome (ACS), defined as a 
sustained increase in IAP above 20 mmHg with new onset 
organ failure, occur commonly in critically ill patients 
[139]. Both are independently associated with morbidity 
(organ dysfunction) and mortality [139, 140]. Around 30% 
of critically ill patients have IAH on admission, and this is 
mainly related to fluid overload, while around 5% develop 
full-blown ACS [139]. In order to establish a diagnosis, IAP 
needs to be measured, the gold standard being via the blad-
der [140]. Mortality of ACS is high when left untreated. The 
kidney is an encapsulated organ, located in the retroperito-
neal space of the abdominal compartment that is especially 
vulnerable to the deleterious effects of increased IAP due 
to the anatomical position and blood supply. The kidney 
is often the first organ that fails when IAP is increased 
and can be considered the canary in the coalmine for IAH 
and ACS [141]. Already in 1873, Wendt E.C. from Ger-
many stated “The higher the abdominal pressure the less 
the secretion of urine,” IAH has been associated with renal 
impairment for over 150 years, but it is only recently that 
Fig. 6 Decrease in perfusate flow, glomerular filtration and sodium 
excretion after stepwise increase in venous pressure in kidneys per‑
fused at constant arterial pressure (from 2)
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a clinically recognized relationship has been found [141]. 
Several animal studies have provided some insights into the 
mechanism of renal dysfunction in IAH [142]. The adverse 
effects of elevated IAP on renal function can already occur 
at lower levels of IAP, before the development of overt ACS 
[142]. An increasing number of large clinical studies have 
identified that IAH is independently associated with renal 
impairment and increased mortality [142]. The mecha-
nisms of renal impairment are not fully understood, but are 
probably multifactorial: reduced renal blood flow, reduced 
cardiac output and increased systemic vascular resistance 
together with alterations in hormonal (plasma renin activ-
ity) and neurogenic factors (Fig.  7). Fluid overload may 
trigger a vicious cycle leading to further kidney and venous 
congestion (especially in patients with sepsis and capillary 
leak with secondary IAH) as shown in (Fig. 8) and should 
be avoided [87]. Hence, diuresis is not a good parameter to 
guide fluid resuscitation in critically ill patients with IAH. 
Elevated IAP significantly decreases renal venous and arte-
rial blood flow leading to renal dysfunction and failure 
[142]. Oliguria usually develops at an IAP of 12–15 mmHg 
and anuria at 25–30  mmHg in the presence of normov-
olemia and at lower levels of IAP in patients with hypov-
olemia or sepsis or under mechanical ventilation with high 
levels of positive end-expiratory pressure [141]. RPP and 
renal filtration gradient (FG) have been proposed as key 
factors in the development of IAP-induced renal failure 
[141].
where MAP = mean arterial pressure
RPP =MAP− IAP
FG = GFP−PTP = (MAP−IAP)−IAP =MAP−2× IAP
where GFP = glomerular filtration pressure, PTP = prox-
imal tubular pressureThus, changes in IAP have a greater 
impact upon renal function and urine production than 
will have changes in MAP. It should not be surprising, 
therefore, that decreased renal function, as evidenced by 
the development of oliguria, is one of the first visible signs 
of IAH. Conversely, therefore it behooves us as clinicians 
to be cognizant of the elevated IAP and its effect on renal 
function is often the first sign of impending ACS. Other 
important issues to remember will be further discussed. 
The pre-renal azotemia seen in IAH is unresponsive to 
volume expansion to a normal CO, dopaminergic or ino-
tropic agents or loop diuretics. The impairment in renal 
function produced by increased IAP seems to be a local 
phenomenon caused by direct renal compression and is 
not solely related to cardiac output. Renal function may 
be improved by paracentesis of the ascitic fluid and sub-
sequent reduction in the IAP. Prompt reduction of IAP 
has dramatic beneficial effect on UO in patients with pri-
mary and secondary ACS after trauma. Within the cap-
sule of the kidney itself, local hematoma formation may 
have an adverse affect on tissue perfusion causing a local 
renal compartment syndrome. The interactions between 
different compartments have been referred to as the 
polycompartment syndrome, and [143] within this con-
cept the compliance may play a major role [144]. Intrigu-
ingly, in advanced heart failure—presumably because of 
low renal perfusion—the kidneys are extremely sensi-
tive to even small elevations in IAP (8–10 mmHg) [145]. 
Moreover, decreasing IAP in such cases, through ultra-
filtration or paracentesis, can dramatically improve renal 
function. Within this regard, it is important to consider 
IAP as a missing link in patients with congestive heart 
failure developing worsening kidney function. This con-
dition has been termed as CARS, cardio-abdominal renal 
syndrome [145]. The best prevention of AKI is preven-
tion of IAH, and the best treatment is treatment of IAH/
ACS. The World Society of the Abdominal Compartment 
has suggested several treatment options, and they can be 
Fig. 7 Possible mechanisms leading to worsening renal failure dur‑
ing increased intra‑abdominal pressure. ADH antidiuretic hormone, 
CO cardiac output, IAP intra‑abdominal pressure, MAP mean arterial 
pressure, NS nervous system, RIP renal interstitial pressure, RPP renal 
perfusion pressure, RVP renal venous pressure
Fig. 8 Vicious cycle leading to fluid accumulation and worsening 
renal failure in patients with hypovolemia or sepsis
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summarized in four major therapeutic approaches: First, 
improvement of abdominal wall compliance, second, 
evacuation of intraluminal contents, third, evacuation of 
abdominal fluid collections and finally, correction of cap-
illary leak and positive fluid balance [140].
RRT management: optimal timing
Deciding when to initiate dialysis in a critically ill patient 
remains one of the most challenging questions in the 
management of critically ill patients. Although several 
approaches have been offered, there is considerable vari-
ation in when dialysis is offered in the ICU setting [146]. 
There is widespread recognition that timing of initiation of 
dialysis is a key area that needs additional research [147]. 
Meta-analysis of trials [147] looking at timing of dialysis 
suggests that there is a signal for improved outcomes with 
earlier starts; however, it is not clear what is the definition 
of early as there are no standard criteria for evaluating tim-
ing of dialysis [148–151]. Several factors have contributed 
to our lack of standardization in this field. Our current 
approach to offering dialysis is strongly conditioned by 
our experience with RRT in patients with end-stage renal 
disease (ESRD) where dialysis is not offered unless there is 
evidence that GFR is 5–10 ml/min and there is evidence 
of complications of uremia [152]. Consequently, our stand-
ard indications for RRT reflect severe derangements in 
renal function including marked acidosis, uremia, severe 
electrolyte problems or diuretic resistant fluid overload. A 
second factor is that in critically ill patients the heteroge-
neity of presentation with multiple organ failure the kid-
ney is often overlooked and less demanding for attention 
when the focus is on improving and maintaining cardiac 
performance. Thirdly, the consequence of process of care 
including aggressive resuscitation may impose significant 
demands on the kidney wherein the normal excretory 
capacity may be overwhelmed. Additionally, underlying 
comorbidities including CKD and heart failure further 
limit the range of renal capacity. Finally, drug and nutri-
tional administration contribute to the demand for fluid 
removal to maintain fluid balance. The dissimilarities of 
the critical care environment from the stable ESRD patient 
thereby highlight the need for different strategies for appli-
cation of RRT. Protocols have been proposed to standard-
ize decisions for RRT initiation but have not been formally 
evaluated [148, 153]. Whereas RRT is by necessity offered 
only as a final resort in ESRD, its application in ICU 
patients should be tailored to the need [154]. We have pro-
posed a simple model to address this conundrum in con-
sidering the relationship of the demands being placed on 
the kidney with the underlying capacity [155]. Using this 
framework, one can characterize patients into four groups 
(Table 6) and develop systematic strategies to address each. 
When demand exceeds capacity, it becomes necessary to 
offer RRT to support renal function. The magnitude of the 
demand capacity mismatch can be quantified and utilized 
to guide therapy initiations and discontinuation. We are 
currently testing a model to validate these concepts. Sev-
eral ongoing studies are also addressing this issue with dif-
ferent strategies. It is anticipated that the concerted effort 
in this area will ultimately provide new data to improve 
our management of these patients.
Dialysis dose in AKI
Introduction
AKI is a common complication of critical illness and is 
associated with high morbidity and mortality. Due to 
the lack of effective drugs, when AKI becomes severe 
enough, RRT is considered the treatment of choice. In the 
past 15 years, many studies have focused on the intensity 
(dose) of RRT in AKI patients. The aim of this brief nar-
rative review is to describe the concept and impact of 
dialysis dose of RRT in AKI patients.
Dialysis dose of RRT in AKI
In 2000, a single-center RCT [156] first reported that 
increased intensity (dose) (35 or 45  ml/kg/h) of CRRT 
was associated with lower mortality (42 or 43%) com-
pared with a dose of 20 ml/kg/h (59%). Furthermore, in 
septic AKI patients, almost twice the survival rate was 
found in the larger dose group (45  ml/kg/h). However, 
these findings have more recently been challenged by two 
large recent multicenter RCTs.
Table 6 Model to initiate and stop dialysis based on assessment of demand and capacity
Demand Capacity Example Action
High Normal High catabolic state
High nutritional loading
Poisoning
Reduce demand if possible
Monitor for support renal support
High Low Decreased GFR from AKI Renal support
Reduce demand if possible
Normal Low CKD
Non‑catabolic
AKI
Add renal support if necessary to maintain steady state
Low Low Malnutrition and wasting CKD Assess for nutritional state and add renal support if necessary
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These two recent key multicenter RCTs, the VA/NIH 
Acute Renal Failure Trial Network (ATN) [157] and the 
Randomized Evaluation of Normal versus Augmented 
Level of Renal Replacement (RENAL) [158] studies found 
that increased intensity (dose) of RRT was not associated 
with improved patient outcomes.
As given in Table  7, the ATN study used a strategy 
that allowed patients to switch between RRT modalities 
according to their hemodynamic status. RRT was pro-
vided as IHD in patients with hemodynamic stability and 
as either CRRT (mostly) or SLED (rarely) when hemody-
namically unstable. No difference of 60-day mortality was 
found between less-intensity therapy arm and intensive 
arm (51.5 vs. 53.6%).
In the second study (the RENAL study), 1508 patients 
were enrolled in 23 ICUs in Australia and New Zealand. 
All participants received CRRT, which were randomly 
assigned at an effluent flow of 25 or 40  ml/kg/h. The 
delivered dose was 22 and 33.4 ml/kg/h, respectively, and 
higher delivered/prescribed dose was found in less-inten-
sity therapy (88 vs. 84%, p < 0.001). The primary outcome 
of 90-day mortality was 44.7% in both arms. In addition, 
both ATN and RENAL studies reported no difference 
in kidney recovery according to dialysis intensity (dose). 
However, hypophosphatemia was more common in the 
higher-intensity group.
These findings now strongly support the view that 
increasing dose intensity above 20–25  ml/kg/h does 
not deliver clinical benefits to critically ill patients with 
severe AKI and have established the current standard of 
care for “intensity (dose) of RRT” such patients.
Intensity of RRT in septic AKI
Sepsis has been reported to account for approximately 
50% of patients with AKI in ICU, and it has been hypoth-
esized that modulation of pro-inflammatory cytokines 
in septic AKI might be beneficial [159]. Accordingly, a 
recent multicenter RCT focused on high-volume hemo-
filtration (HVHF) for septic AKI patients. The IVOIRE 
(hIgh VOlume in Intensive caRE) study [160] enrolled 
140 AKI patients with septic shock from 18 ICUs in 
Europe and compared the efficacy of HVHF (70  ml/
kg/h) with standard-volume hemofiltration (35 ml/kg/h). 
Although higher clearance of some solute (urea and cre-
atinine) was reported in the HVHF group, there was no 
difference in 28-day or 90-day mortality between the two 
groups.
Two recent meta-analyses have further evaluated 
the issue of RRT intensity in AKI. Van Wert et al. [161] 
assessed 12 studies with 3999 patients, including 7 stud-
ies of CRRT, 3 of IHD, 1 of SLED and 1 of all three. These 
investigators found no benefit of more intensive RRT 
with regard to survival or dialysis dependence among 
survivors. A second meta-analysis [162] focused on 
HVHF (>50  ml/kg/h) for septic AKI patients and also 
found no difference in mortality between HVHF and 
standard-volume hemofiltration, but identified signifi-
cantly higher rates of hypophosphatemia and hypoka-
lemia in HVHF-treated patients.
As a consequence, the “Disease: Improving Global 
Outcomes (KDIGO)” AKI clinical practice guidelines 
[91] recommended that the “normal (standard) dose” 
of CRRT should in the range of 20–25 ml/kg/h and also 
recommended that, if IHD or SLED is chosen as the RRT 
modality for AKI, they should be set to deliver a Kt/V of 
3.9 per week.
Potential disadvantages of high intensity
There might be some potential complications which may 
counterbalance the advantage of higher clearance in 
high-intensity RRT. First, intensified therapy is reported 
to be associated with electrolyte disturbances such as 
Table 7 Characters of ATN, RENAL and IVOIRE studies
AKI acute kidney injury, CVVH continuous venous–venous hemofiltration, CVVHDF continuous venous–venous hemodiafiltration, SLED sustained low-efficiency 
dialysis, IHD intermittent hemodialysis
ATN RENAL IVOIRE
Design Multicenter RCT Multicenter RCT Multicenter RCT
Country USA Australia and New Zealand France, Belgium and Netherlands
Patients AKI AKI AKI with septic shock
No. of patients 1124 1508 140
Modality CVVHDF, SLED, IHD CVVHDF CVVH
Prescribed dose CVVHDF: 21.5 versus 36.2 ml/kg/h
SLED and IHD: 3 versus 6/wk
25 versus 40 ml/kg/h 35 versus 70 ml/kg/h
Delivered dose CVVHDF: 22 versus 35.8 ml/kg/h
SLED: 2.9 versus 6.2/wk
IHD: 3 versus 5.4/wk
22 versus 33.4 ml/kg/h 33.2 versus 65.6 ml/kg/h
Mortality 60 days
51.5 versus 53.6%
90 days
44.7 versus 44.7%
90 days
50.7 versus 56.1%
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hypophosphatemia or hypokalemia, which may do harm 
to renal, cellular, respiratory or cardiac function. Second, 
more attention should be focused on nutritional losses 
during CRRT. Increasing the intensity of RRT may dou-
ble or triple the amount of amino acid or protein losses 
[163], as well as many micronutrient losses such as vita-
mins, selenium and folic acid [164]. Third, many antibiot-
ics can be cleared significantly by RRT, and high-intensity 
RRT would make it more complicated to adjust the dose 
of antibiotics and could potentially generate periods of 
inadequate antibiotic levels, which, in turn, may impede 
the efficacy of antimicrobial therapy. Lastly, the RENAL 
study [158] found that high-intensity CRRT required 
more filters per day, indicating more clotting events and 
frequent interruption occurred during therapy. This 
effect could generate more costs, more manipulation and 
more red cell losses, which could also impact on patient 
well-being.
Other aspects of dose
The concept of the impact of dose on outcome has been 
explored only in terms of solute control. However, the 
term “dose” implies other aspects of RRT beyond solute 
control: volume control; timing of intervention; acid–
base control; electrolyte control; and nutritional therapy 
optimization. Unfortunately, no RCTs have been con-
ducted to test whether different modalities and/or tech-
niques and/or intensity of RRT application can lead to 
different outcomes in relation to such more complex 
or extended aspects of “dose.” Despite such limitations, 
strong observational data [165, 166] have repeatedly 
found a clear correlation between a positive fluid balance 
and unfavorable outcome, suggesting that volume control 
may be an important to patient outcome as solute clear-
ance (Fig. 9).
Conclusions
There is no convincing evidence supporting the view 
that more intensive RRT can improve outcomes in AKI 
or septic AKI. At present, 20–25  ml/kg/h of effluent 
flow rate is recommended for CRRT practice, although 
sometimes effluent flow rates may need to be increased if 
there are frequent or prolonged interruptions of therapy. 
Kt/V remains the common available method of monitor-
ing solute removal dose of IHD or SLED in AKI patients. 
However, adequacy of volume management and fluid bal-
ance should be also considered as an important “marker” 
for the intensity of therapy and requires targeted rand-
omized controlled trials.
Anticoagulation management in continuous RRT (CRRT)
Upon contact of blood with foreign material, blood cells 
and molecular pathways are triggered causing activation 
of coagulation and inflammation. Although biomaterials 
have improved, we still need anticoagulation to suppress 
this reaction and allow adequate hemodialysis or hemo-
filtration, especially during critical illness when coagula-
tion is activated and natural anticoagulants are low.
Main anticoagulant measures include heparin and cit-
rate. Additional non-anticoagulant measures such as low-
ering filtration fraction and pre-dilution, straight catheter 
course, avoidance of side holes and limiting blood-air 
contact are worthwhile [167].
Heparin Heparin inhibits thrombin formation by 
potentiating antithrombin and inhibiting factor XIIa. 
During critical illness, heparin has several drawbacks. 
Apart from circuit anticoagulation, heparin causes sys-
temic anticoagulation and thereby increases bleeding 
risk. Furthermore, critical illness confers heparin resist-
ance, because antithrombin may be low. Moreover, 
heparin binds to acute phase proteins and necrotic and 
apoptotic cells. Finally, heparin has pro-inflammatory 
effects by triggering the release of granular products 
from polymorph leukocytes and platelets [168].
Citrate. Citrate inhibits thrombin formation by 
decreasing ionized calcium (iCa), cofactor in the coagu-
lation cascade. Because citrate is rapidly metabolized 
when entering the patient, citrate provides regional anti-
coagulation and does not increase bleeding risk. Citrate 
also inhibits the activation of granulocytes and plate-
lets upon membrane contact and therefore increases 
biocompatibility.
Citrate versus heparin Randomized studies show that 
citrate is better tolerated, confers less bleeding, longer 
circuit life, a higher delivered dose and reduces the costs 
of CRRT [169].
Citrate: anticoagulant, buffer and fuel The use of citrate 
is, however, complex, because citrate is both anticoagu-
lant and buffer. Anticoagulation depends on the chela-
tion if calcium and thus on the citrate concentration in 
the filter blood. Anticoagulation starts when iCa falls 
below 0.5 mmol/l and is maximal below 0.25 mmol/l. In 
contrast, the buffer strength depends on the amount of 
Fig. 9 90‑day mortality of RRT‑treated AKI patients who were posi‑
tive versus negative for the presence of fluid overload in RENAL and 
FINNAKI studies
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unopposed strong anion entering in the patient’s circula-
tion. The strong anion is most often sodium, but if acid 
citrate dextrose (ACD-A) is used, part of the anions are 
hydrogen, reducing buffer strength [170]. After metabo-
lism of citrate, the unopposed sodium exerts the alkaliz-
ing effects by increasing the strong anion difference.
Citrate(C6H5O7) confers energy 0.59  kcal/mmol. One 
day of citrate CRRT provides 350–500 kcal, depending on 
the modality. However, ACD-A delivers up to 1000 kcal 
per day due to the associated glucose load. When lactate 
is used as buffer, about 550  kcal are delivered per day 
[170].
Limitations The safe use of citrate is limited by its 
metabolism in the mitochondria of liver, kidney and 
muscle. Mitochondrial metabolism is oxygen depend-
ent. When citrate is not metabolized, it accumulates and 
lowers systemic iCa concentration. Total calcium (totCa) 
rises due to citrate chelation and calcium replacement. 
A rise in total to iCa ratio above 2.5 is the most specific 
warning sign of accumulation. Because citrate is not 
metabolized, SID increases less and metabolic acidosis 
can develop. Lactate concentration may be high, but not 
due to citrate accumulation but to underlying disease. 
Risk factors for accumulation are decompensated liver 
cirrhosis, severe systemic hypoperfusion and possibly 
sarcopenia: diseases associated with tissue hypoxia or 
loss of mitochondrial capacity. Although the incidence of 
citrate accumulation is low (1–3%) [171], its occurrence 
is associated with high mortality (up to 100%) due to 
underlying disease.
Citrate and lactate A lactate above 3.4  mmol/l was 
found to be predictive of citrate accumulation in patients 
with liver failure. However, adequate control of acido-
sis and no major electrolyte disturbances were observed 
despite a Ca ratio above 2.5 in 16% of the runs [172]. 
We questioned our database whether a lactate concen-
tration above 4  mmol/l predicted citrate accumula-
tion. We found that after 12 h, citrate accumulation (Ca 
ratio  >  2.5) developed in 15/694 (2.2%) of the patients 
with lactate below 4  mmol/l and in 8/67 (10.9%) when 
lactate was above 4 mmol/l. Reason may be that during 
systemic inflammation hyperlactatemia is partially due to 
increased aerobic glycolysis, not to tissue hypoxia. Thus, 
a high lactate is not a contraindication for citrate antico-
agulation per se and the risk of accumulation should be 
weighed against the risk of bleeding when using hepa-
rin or early clotting without anticoagulation. However, 
withholding citrate should be considered in case of a 
high lactate due to persisting systemic hypoperfusion or 
decompensated liver cirrhosis.
Citrate monitoring Monitoring of citrate includes iCa, 
acid base and totCa. Systemic iCa is used to guide cal-
cium replacement. When both iCa and totCa decrease, 
calcium replacement should be increased. If iCa is low 
and the totCa/iCa ratio rises, citrate is accumulating. 
Whether we should stop citrate if Ca ratio is above 2.5 
depends on metabolic control. If acid base is in equilib-
rium and iCa within range with additional replacement, 
citrate can be continued with close monitoring if risk of 
bleeding is increased.
The benefits and limitations of citrate are summarized 
in Table 8.
Conclusion
Citrate is first-choice anticoagulant in CRRT, but invest 
in understanding, stick to the protocol and monitor 
accumulation.
SLEDD
The treatment of AKI in the ICUs knew some revolu-
tions in the last twenty years, in particular in terms of 
techniques used, with the switch from nephrologists 
taking care to intensivist’s autonomy. IHD let place to 
CRRT, especially CVVH which is the most popular tech-
nique worldwide. But some hybrid techniques appeared, 
between CVVH and IHD, as sustained low-efficiency 
daily dialysis (SLEDD), that seem combined the advan-
tages of the two older techniques [173].
In fact, there are very few studies and publications 
about SLEDD and its use remains confidential in the 
world. The technique seems to have some advantages in 
comparison with IHD as lower blood flow, slower fluid 
removal and solute clearance and less hemodynamic 
instability with a good solute control, the price is longer 
sessions (about 8–16 h). However, longer sessions imply 
increasing risk of circuit thrombosis and anticoagulation 
is often necessary at the same level as for CVVH.
Some studies have been completed in the last decade, 
but most of them were retrospective or observational 
studies with small sample size of patients and controver-
sial results. A randomized controlled trial was published 
Table 8 Summary of the benefits and limitations of citrate 
anticoagulation
CRRT continuous renal replacement therapy, iCa ionized calcium
Benefits Limitations Monitoring
Compared to heparin
 Safety ↑
 Tolerance ↑
 Risk of bleeding ↓
 Circuit life ↑
 Delivered CRRT 
dose ↑
 Biocompatibility ↑
 Cheaper
Accumulation in 
case of persistent 
hypoperfusion and 
decreased mito‑
chondrial capacity
Difficult to understand
Strict protocol is 
needed
Adherence to the pro‑
tocol is required
Systemic iCa and acid 
base balance 6–8 
hourly
Total calcium and total/
iCa ratio once daily or 
more frequently if the 
risk of accumulation 
is high
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in 2012, with 115 patients included, comparing CVVH to 
SLEDD, showing that SLEDD was cheaper and reduced 
nursing time but without any clinical benefit [174]. 
Moreover, while SLEDD was done perfectly, CVVH 
treatment was inadequate with all the replacement 
fluid given in pre-dilution and with a filtration fraction 
about 29%. More recently, Zhang provided a meta-anal-
ysis that showed similar survival between CRRT and 
SLEDD and with a lower mortality in the SLEDD group 
when only observational studies are taking into account 
[175]. However, the sample size of observational stud-
ies is quite low (only 675 patients in 10 studies) and is 
potentially subject to allocation or selection bias. More-
over, a meta-analysis using only 7 RCTs was negative 
with in addition included a study from Egypt with only 
80 patients but representing 30% weight in the analy-
sis. [176]. Then, all these studies are underpowered and 
mostly observational and do not brought any signs of 
superiority for SLEDD in terms of outcome, solute con-
trol or metabolic equilibrium.
There are two possible benefits for SLEDD technique, 
the low cost and the time without therapy to mobilize 
the patient. In fact, financial benefit with SLEDD is really 
major when we use the specific machine with water treat-
ment for dialysis solute, as the only cost is the price of 
the machine and the circuit/membrane consumables. But 
in that case you can only use the machine for SLEDD, 
when it is possible to use all the techniques (IHD, CVVH 
and plasmapheresis) with the new devices. Mobilization 
of patients is a major challenge in the modern ICUs, and 
intermittent techniques for RRT are superior in that case 
as we are able to treat the patients during the night and 
mobilize them during the day. But during the acute phase 
while mobilization is scarce and not priority this advan-
tage is not crucial. The last but not least problem is with 
antibiotics, especially during the acute phase of sepsis, as 
the management of dosing is very difficult during RRT 
and is probably better to favor continuous methods than 
intermittent ones.
Finally, SLEDD is a hybrid technique between CVVH 
and IHD, with some advantages of the two methods but 
also disadvantages. The lack of strong studies and the 
relative low development of SLEDD in the world do not 
push physicians to use it. Clearly the main advantage of 
the technique is the low cost and the possibility of early 
mobilization of the patients. But the difficulty of antibi-
otics management, intermittent procedure that is not 
the best way for hemodynamic unstable patients and 
low level of middle size molecules clearance may limit 
its indication during the acute phase of AKI. The place of 
SLEDD might be during the chronic phase and should be 
explored in this way.
How to assess recovery from AKI?
Whether or not the kidney recovers from an episode of 
AKI has important prognostic implications [177] and 
therefore deserves a correct assessment. At this moment, 
there is no consensus on the optimal timing to determine 
AKI recovery. For reasons of convenience, it is mostly 
assessed at hospital discharge, but others argue that the 
optimal timing would be 3 months after the start of AKI, 
because that is the earliest time-point that a formal diag-
nosis of CKD can be made [178].
Consensus on how to assess recovery is also lacking. 
The most commonly used parameters are: the absence of 
AKI criteria, the return to baseline creatinine or to within 
1.1 or 1.25 times baseline, a 50% decrease from peak cre-
atinine, a discharge creatinine that is less than 0.3 mg/dL 
above baseline, discharge CKD class or return to baseline 
eGFR. A recent analysis has demonstrated important dif-
ferences in the proportion of complete recovery accord-
ing to the severity of AKI and the definitions applied 
[179]. Some studies report renal recovery in survivors 
only, whereas others include the whole AKI population. 
It is evident that this will also affect the results. Whether 
the whole population or only survivors should be consid-
ered depends on the context. From a patient’s perspec-
tive and when the focus is on the need for nephrological 
follow-up, recovery in survivors is most meaningful. On 
the other hand, in an intervention trial on a therapeu-
tic strategy to promote recovery, the whole population 
should be considered with mortality as a competing end-
point. While awaiting a consensus definition, it is impor-
tant that studies on AKI recovery clearly describe their 
definitions, the population under evaluation, the severity 
of AKI and the proportion of CKD patients [179].
Another important drawback is that recovery in clinical 
settings is not evaluated with a gold-standard GFR meas-
urement (e.g., insulin clearance) but with the only GFR 
parameters that are clinically available, i.e., either SCr or 
the derived eGFR that are compared with their baseline. 
This assessment assumes that the relationship between 
the true GFR on the one hand and creatinine and the 
derived eGFR on the other does not change during ICU 
stay. It is well known, however, that ICU patients, espe-
cially those with prolonged stay, develop muscle wasting 
with decreased creatinine generation. This may result 
in overestimation of recovery. The impact of this gen-
erally acknowledged phenomenon on the assessment 
of recovery has recently been quantified by comparing 
eGFR with the measured 24  h CCr at ICU discharge in 
AKI patients with different ICU stays. Whereas the two 
GFR measurements did not differ in patients with ICU 
stay below 7 days, eGFR became significantly higher than 
24 h CCr in patients with ICU stay between 8 and 14 day, 
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and this difference further increased in those with ICU 
stay above 14 days (Fig. 10a). As a result, assessing recov-
ery with the 24 h CCr instead of the eGFR substantially 
reduced the incidence of complete recovery: In patients 
with ICU stay above 14 days it decreased from 60 to 30%. 
Measured creatinine excretion, as a parameter of muscle 
mass, decreased with increasing ICU stay and became 
significantly lower that the predicted creatinine genera-
tion (based on gender, age and weight) from an ICU stay 
above 7  days. Interestingly, the same results were seen 
in patients without AKI: here too the discharge eGFR 
was significantly higher than the 24  h CCr (Fig.  10b) 
and the creatinine excretion was significantly lower than 
the predicted generation in patients with longer ICU 
stay. In addition, the discharge creatinine in these long-
stay patients was lower than baseline, again pointing to 
important muscle loss. The conclusion from this analysis 
is that comparing discharge eGFR or SCr with their base-
line significantly overestimates recovery in patients with 
longer ICU stay. This also suggests that further increases 
of SCr after discharge do not necessarily point to further 
deterioration of kidney function but may simply reflect 
the restitution of muscle mass during revalidation [180].
Can we predict recovery? Reported risk factors for 
non-recovery are older age, pre-morbid GFR, comor-
bidity (e.g., diabetes), illness severity, cause and severity 
of AKI, fluid overload and modality of RRT [181]. More 
recent investigations have evaluated the accuracy of bio-
markers for the prediction of (non)-recovery [182]. The 
available studies are small, and more research is needed.
In conclusion, timing and methods for assessing recov-
ery from AKI significantly affect the results. The timing 
of recovery assessment should take into account mus-
cle wasting during hospital stay. Consensus on when 
and how to determine recovery from AKI should be 
established.
AKI: long‑term outcomes
Introduction
The strong and independent relationship between AKI 
and short-term mortality is well described in medical and 
surgical patients, in general ICU patients and in multi-
trauma patients [26]. Nearly half of patients with severe 
AKI, requiring RRT, die during hospital admission. In 
addition, major adverse long-term consequences in AKI 
survivors have been documented [177, 183–185]. The 
Fig. 10 a eGFR (gray boxplots) and Clcr (white boxplots) (in ml/min/1.73 m2) at ICU discharge for subgroups of AKI patients with ICU stay <7 days, 
7–14 days and >14 days. Boxplots show median and IQR, whiskers 10th and 90th percentile. b eGFR (gray boxplots) and Clcr (white boxplots) (in ml/
min/1.73 m2) at ICU discharge for subgroups of non‑AKI patients with ICU stay <7 days, 7–14 days and >14 days. Boxplots show median and IQR, 
whiskers 10th and 90th percentile (from [4]—with permission)
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aim of this narrative review is to describe such long-term 
complications. We focus on AKI survivors’ renal recovery 
or lack thereof, the link between post-ICU renal morbid-
ity and mortality and, finally, AKI survivors’ perception 
of their quality of life.
AKI survivors’ long‑term risk of CKD, ESRD 
and cardiovascular death
Depending on AKI severity and the presence or absence 
of pre-morbid CKD, approximately 2–30% of AKI sur-
vivors progress to ESRD and lifelong need for dialysis 
within 2–5 years after ICU discharge (Table 9) [177, 183, 
184, 186–188]. Of 810 survivors to day 90 after severe 
AKI, requiring CRRT in the Randomized Evaluation 
of Normal versus Augmented Levels of RRT (POST-
RENAL) study, 5.4% were dialysis dependent within 
a mean of 3.6  years [2]. CRRT intensity in ICU had no 
significant impact on the subsequent need for chronic 
dialysis. AKI severity, CKD and their relationship with 
non-renal recovery were further demonstrated in AKI 
survivors after major surgery [187]. Patients with severe 
postoperative AKI (of which 18.8% received acute dialy-
sis) had an ESRD incidence of 5.1% (independent 22-fold 
increased risk compared to non-AKI patients) during 
a median follow-up of 4.8  years. In contrast, the cor-
responding incidence was 0.6% in mild AKI patients 
(doubled risk) and 0.3% in patients without AKI. In 
comparison, acute-on-CKD was independently associ-
ated with a 123-fold risk of progression to ESRD.
Even in patients with apparently normal baseline kid-
ney function, the risk of progressive renal dysfunction 
is significant after AKI. In a Swedish cohort of almost 
100,000 critically ill patients without pre-ICU kidney dis-
ease, approximately 5000 had AKI. Of these AKI patients, 
almost 3000 patients were still alive at day 90 [184]. 
During a median follow-up of 3.2  years, 21.8% of these 
patients died and 2.2% developed ESRD. In addition, 
6.5% were diagnosed with de novo CKD (not requiring 
dialysis) in the national patient register during follow-
up. Compared to non-AKI patients, these AKI survivors 
had an almost threefold increased mortality risk, a sev-
enfold increased risk of developing CKD and a 22-fold 
higher risk of developing ESRD. Similar incidences were 
observed in a Canadian cohort of survivors of hospital-
acquired AKI assessed over a median of 2.8 years; 30.8% 
died and 2.1% developed ESRD [177]. Furthermore, in 
the same study, another 10% had a sustained a doubling 
of their SCr during follow-up. Finally, 42.1% of AKI sur-
vivors had albuminuria during follow-up in the POST-
RENAL study suggesting persisting kidney damage in 
these patients [183].
CKD is a well-known risk factor for cardiovascular 
events and mortality [189], and both likely connect AKI 
with increased long-term mortality. In fact, patients 
Table 9 AKI survivors and their long‑term incidences and relative risks of mortality, CKD and ESRD
AKI acute kidney injury, CKD chronic kidney disease, ESRD end-stage renal disease, D-AKI AKI requiring dialysis in ICU, NR not reported
a Mean or median follow-up
b Adjusted mortality rate ratio, incidence rate ratio, hazard ratio or odds ratio relative non-AKI patients or AKI recovery
c Considering survivors to hospital discharge
d Considering 90-day survivors
e Considering 180-day survivors
Authors  
[reference]
AKI severity Study (n) Follow‑upa 
(years)
Mortality CKD ESRD
% Relative  riskb 
(95% CI)
% Relative  riskb 
(95% CI)
% Relative  riskb 
(95% CI)
Ishani et al. [6] AKI only
AKI + CKD
233,803 2.0c 54.3
64.3
2.48 (2.38–2.58)
3.24 (3.08–3.40)
NR NR 2.5 13.0 (10.6–16.0)
41.2 (34.6–49.1)
Wu et al. [7] AKI only
Mild AKI
Moderate AKI
Severe AKI
AKI + CKD
9425 4.8c 33.3
27.4
39.1
45.0
47.2
1.62 (1.45–1.81)
2.41 (2.11–2.75)
3.06 (2.66–3.53)
3.58 (2.91–4.41)
NR NR 1.9
0.6
0.7
5.1
30.3
2.09 (0.97–4.52)
3.19 (1.27–8.03)
22.35 (11.9–42.1)
122.9 (66.8–253.9)
Pannu et al. [3] AKI ± CKD
AKI recovery
AKI non‑recovery
190,714 2.8d 30.8 1.0
1.26 (1.10, 1.43)
9.8 1.0
4.13 (3.38, 5.04)
2.1 NR
Gammelager et al. 
[8]
D‑AKI ± CKD
D‑AKI only
D‑AKI + CKD
107,937 3.1e NR NR NR NR 3.8 6.2 (4.7–8.1)c 
11.9 (8.5–16.8)
2.8 (1.8–4.3)
Gallagher et al. [2] D‑AKI ± CKD 810 3.6d 31.9 NR NR NR 5.4 NR
Rimes‑Stigare 
et al. [4]
AKI only 97,782 3.2d 21.8 1.15 (1.09–1.21) 6.5 7.6 (5.5–10.4) 2.2 22.5 (12.9–39.1)
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with myocardial infarction (MI) complicated by AKI had 
higher risk of stroke, congestive heart failure, new myo-
cardial infarction or death during 6  years of follow-up 
compared to patients with MI but without AKI [190].
The above-mentioned studies support the notion that 
AKI is a springboard to de novo CKD as well as to accel-
erated CKD progression, cardiovascular morbidity and 
mortality [190, 191]. Importantly, even transient AKI 
episodes resolving within 90 days after hospital discharge 
has been associated with a twofold increased risk of later 
CKD development [192]. Longitudinal surveillance of 
kidney function beyond 90 days therefore appears justi-
fied in AKI survivors.
AKI survivors’ quality of life
Results from quality-of-life (QoL) assessments in criti-
cally ill patients with and without AKI are conflicting. 
Previous studies suggested poor long-term health-related 
QoL as a consequence of AKI in ICU [193, 194]. Reduced 
physical health compared to matched reference popula-
tions was mainly reported whereas self-reported mental 
health was less affected.
More recent studies suggest, however, that ICU 
patients’ QoL may be reduced already before ICU admis-
sion [195, 196]. Hofhuis et al. assessed pre-ICU QoL by 
proxy using Short-Form (SF)-36 and demonstrated sig-
nificantly lower scores compared to an age-matched 
population [196]. In addition, after 6 months, survivors’ 
self-reported SF-36 score was significantly lower than 
their proxy-reported baseline score. No major difference 
between patients with and without AKI was found at the 
end of follow-up.
Similar results were found in the FINNAKI study [195]. 
The Euro Quality of life (EQ)-5D index was significantly 
lower on ICU admission as compared to an age- and sex-
matched general population. Additionally, EQ-5D index 
was similar between AKI and non-AKI patients and, in 
contrast to the study by Hofhuis et  al., did not change 
significantly during 6-month follow-up. In contrast, the 
perceived 6-month QoL (Visual Analogue Scale [VAS] 
component of EQ-5D) was similar to that of the reference 
cohort in all but the patients treated with RRT in ICU 
who had significantly reduced scores.
Health-related QoL in patients treated with RRT in 
ICU was assessed by using the SF-12 questionnaire in 
the POST-RENAL study [185]. Compared to the general 
population, the POST-RENAL patients had significantly 
lower physical and mental scores 3.5 years after ICU dis-
charge. Importantly, the presence of albuminuria as an 
indicator of chronic kidney damage was independently 
associated with reductions in the physical component 
score of the SF-12.
Conclusions
Severe AKI is a serious complication in critically ill 
patients and is associated with a high short-term mor-
tality rate. Moreover, even mild and transient episodes 
of AKI appear to increase the long-term risks of chronic 
and end-stage renal disease and cardiovascular morbid-
ity among survivors. Finally, evolution from acute to such 
chronic renal conditions likely explains the extremely 
high 5-year mortality seen in AKI patients as well as the 
reduced QoL in survivors after severe AKI. These find-
ings suggest
Control of host response with extracorporeal purification 
techniques
Sepsis remains the leading cause of death in ICUs nowa-
days, and the dream to find a technique to control host 
response is more alive than ever. Many techniques have 
been explored in this indication with good hopes after 
animal and preliminary studies but were disappointing 
after negative large randomized studies.
The idea to control sepsis start in the early nineties, 
with a study from Grootendorst, where pigs were hemo-
filtrated and effluent infused in healthy pigs, and they 
became sick and died only when effluent came from sep-
tic pigs and not when it came from healthy pigs. They 
proved for the first time that we were able to remove “bad 
humors” from septic animals and may control sepsis by 
this way [197]. From this point, many studies were con-
ducted and blood purification techniques tested: HVHF, 
HCO membrane (HCO), plasmapheresis, adsorption 
and derived techniques (as coupled plasmafiltration and 
adsorption (CPFA), with variable results.
All these adjunctive treatments have the same objec-
tive; remove cytokines and other inflammatory or anti-
inflammatory mediators to control the evolution of 
sepsis. Some theories have been developed to try to 
explain the potential interest of blood purification tech-
niques. First the “peak concentration hypothesis” leaded 
by Ronco who hypothesized that the removal of delete-
rious peak of mediators secreted during sepsis by blood 
purification may control host response and avoid organ 
dysfunction. Then, Honoré thought that hemofiltra-
tion is also able to remove mediators from tissue in the 
“threshold modulation theory.” And last, Di Carlo with 
“the mediator delivery hypothesis” explained that media-
tors’ removal is more due to lymphatic wash-out by large 
volume of crystalloids infusion (which is the case during 
hemofiltration) than by removal in the effluent [198]. But 
unfortunately, our knowledge on immunology and sep-
sis is not sufficient to understand exactly what we have 
to remove and when to control host response in our 
patients.
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In the last decade, important studies brought some 
answers about the efficacy of those techniques to 
decrease mortality in sepsis and to remove mediators. 
Only one large study with plasmapheresis has been com-
pleted, in Russia, a RCT with 106 septic shock patients 
included and a better survival for those treated by plas-
mapheresis. But this study is the lone study with these 
results and has not been reproduced [199]. Some RCTs 
were done with HCO membrane but not published yet 
and without positive results. A large multicenter RCT 
with HVHF tested (70  ml/kg/h) versus standard hemo-
filtration (35  ml/kg/h) on 140 septic shock patients 
included failed to show any benefit of HVHF [160] and 
confirmed the results of a monocenter Chinese RCT with 
280 patients included comparing 50 ml/kg/h with 80 ml/
kg/h. Also a large multicenter RCT in Italy with CPFA 
has been stopped prematurely for futility. More, a French 
RCT about hemofiltration started early (before AKI) 
in septic patients has been terminated prematurely for 
safety due to higher SOFA in the hemofiltration group in 
comparison with standard treatment [200]. Finally, only 
animal studies and small randomized or non-randomized 
human studies found positive results, when all the RCTs 
were negative but that one about plasmapheresis. One 
explanation is that we remove “bad things” with blood 
purification but also a lot of “good things” like antibiot-
ics, vitamins or good mediators which is possibly more 
deleterious than host control is beneficial [200].
Currently, control of host response with blood purifica-
tion techniques remains a dream. We continue to study 
new techniques, but with the results of last RCTs it is 
not reasonable to use them in routine practice or outside 
research protocols. Next studies should focus on reduc-
ing the deleterious impact of blood purification on anti-
biotics and vitamins removal to have a chance to reveal 
the possible benefit of immunomodulation in our septic 
patients.
Extracorporeal epuration: beyond the kidney, the control 
of pathogen
By definition, the syndrome called sepsis implies a sys-
temic inflammation, which changes the blood content 
with activated immune cells, release of mediators and 
hormones and presence of pathogen-related molecule 
(PAMPs) or tissue damage molecule (DAMPs). These 
modifications differ along time evolution of sepsis cor-
responding to modifications in blood constitution being 
responsible for waves of up- or down-regulation of 
inflammation [201]. The models using ex vivo or in vitro 
experiments with plasma from septic patients or animals 
have confirmed the presence of molecules in plasma 
that may alter cellular functions, even for healthy cells. 
As a consequence, “cleaning the blood or plasma” using 
extracorporeal circuit with different membranes or car-
tridges removing molecules by convection/adsorption/
filtration is attractive for clinicians, despite the recent 
disappointing results of randomized clinical trials [200]. 
Recently, important proofs for an inflammatory media-
tion of septic-induced AKI have been reported, stimu-
lating the development of cartridges targeting different 
plasma molecules [202] with the hope to control sys-
temic inflammation. However, the targeted molecules 
to be removed remain elusive, since the knowledge of 
the positive versus negative components remains a chal-
lenge for clinician that is not clarified by the actual bio-
markers, cell functions evaluation tests or tissue function 
tests. Although inflammation and kidney infiltration 
have been demonstrated to induce AKI, some infiltra-
tion might be protective for the tissues. As an example, 
the inflammatory monocyte (newly recruited) adhesion 
to renal vascular wall orchestrated by CX3CR1 activa-
tion has been shown to be protective for kidney injury in 
rat and human beings [203]. The I249 CX3CR1 allele is 
associated with both increased monocyte adhesiveness 
and reduced kidney damage in human septic shock. The 
strategy of care should focus on components well admit-
ted to induce inflammation and/or tissue damage such as 
endotoxin or activated cells or both.
The plasma removal of endotoxin (EDTX) is seen as a 
hope to reduce inflammation during the acute phase of 
severe sepsis. The polymyxin B hemoperfusion to remove 
EDTX is used for several years in Japan as a routine ther-
apy in septic shock. Before promoting this technique for 
a generalized use, randomized control trials have to prove 
the benefit for outcome parameters such as a reduced 
mortality, intensity of organ failure and length of stay. 
In this prospect, a first RCT has been reported in sep-
tic shock induced by an acute peritonitis in JAMA [204]. 
Despite the small number of enrolled patients (64) and 
the absence of EDTX plasma level measurements, this 
multicenter trial showed in a post hoc analysis a reduc-
tion in mortality rate at day 28 between control (53%) 
and treated groups (32%), with a decrease in vasopressor 
requirement. Recently, the prospective RCT performed 
on 232 septic shock patients related to peritonitis has 
been published [205]. Hemoperfusion with PMX mem-
brane had no benefit on mortality at day 28 and day 90. 
Even after classification based on systemic inflamma-
tory intensity (plasma IL-6 level), completion of 2 PMX 
sessions, after selection on surgical adequacy of surgical 
procedure, PMX hemoperfusion did not show any ben-
efits on mortality. This RCT may have some limitations 
such as the relative modest number of patients and the 
absence of ET measurements. However, some posi-
tive aspects have to be also considered: the assessment 
of surgical procedure quality usually not quoted, the 
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postoperative time delay to enroll the patients to reduce 
the anesthetic impact on hypotension, the protocolized 
cardiovascular resuscitation.
To conclude, even the concept of the control or 
removal of plasma mediators, especially EDTX remains 
attractive, no real proven benefit for outcome has been 
reported until now. The ongoing larger RCT in the USA 
(EUPHRATES) enrolling a larger number of septic shock 
patients with a high level of EDTX level will bring a 
definitive answer to the benefit of such a therapy.
Liver support systems
Introduction
The significant array of liver support systems available 
would suggest that the design, clinical utilization and end 
points for success remain poorly defined.
The literature is peppered with case series suggesting 
benefit and randomized controlled trials (RCT) that have 
failed to deliver mortality benefit.
Systems can be divided into (a) cleansing systems, (b) 
biological systems and (c) cellular transplantation.
The patient groups that these systems have been 
applied to are acute-on-chronic liver failure (AoCLF), 
alcoholic hepatitis, acute liver failure (ALF) and stable 
cirrhotics with profound pruritus.
The aims of any support system may be defined as 
biochemical improvement (bilirubin, direct and indi-
rect and ammonia), clinical parameters (hemodynamic 
status, grade of hepatic encephalopathy (HE), coagula-
tion parameters, pruritic scores) along with cytokines 
and immune function. In the patient with acute liver 
failure, there is a desire to stabilize and promote spon-
taneous liver regeneration and in the AOCLF, to sta-
bilize and allow time for liver transplantation to be 
undertaken. There has been less examination of the 
role of such systems in hypoxic hepatitis or septic liver 
dysfunction.
Cleansing systems
These may be considered standard renal replacement 
therapy (RRT), albumin dialysis systems, of which MARS 
is the most commonly reported where counter current 
to blood is run an albumin circuit within which there 
are adsorbent columns and renal filters. Plasma separa-
tion and adsorption are represented by Prometheus sys-
tem where plasma is run over an adsorbent column and a 
renal dialysis filter prior to return to the patient. Plasma 
exchange is simple cleansing process exchanging the 
patient plasma with fresh-frozen plasma on a 1:1 ratio.
Biological systems. Single-pass albumin dialysis pro-
vides counter current slow dialysis (700  ml/min) of a 
solution of 5% albumin in a standard hemofiltration solu-
tion [206].
Biological systems
These systems usually incorporate plasma separation; the 
plasma is then cleansed using an adsorbent column and 
is then run across hepatocytes (porcine or hepatoblas-
toma) and the treated plasma returned to the patient. The 
most commonly referenced systems are the bioartificial 
liver system (BAL) and extracorporeal liver assist device 
(ELAD) but others have also described and reported 
systems.
A more extreme form of biological liver support could 
be considered hepatocyte transplantation and auxiliary 
liver transplantation.
Effects of therapies and end points
The effect of volume therapy has been reported to result 
in an 18% reduction in bilirubin [207], while by con-
trast increasing albumin levels increases bilirubin and 
decreases clearance when albumin dialysis is undertaken.
Acute kidney injury further contributes to impaired 
ammonia clearance in cirrhosis and institution of RRT 
decreases ammonia significantly [119] and rate of 
removal correlates with urea clearance.
Single-pass albumin dialysis (SPAD) studies have 
shown, in a rig, excellent clearance of ammonia, bile 
acids and bilirubin [206].
Studies with MARS have clearly shown improvement 
in biochemical parameters in several studies with falls in 
bilirubin, renal parameters and ammonia [208]. Equally 
frequently reported have been an improvement in hemo-
dynamics and inflammatory cytokines. A RCT examining 
HE [208] in 70 patients demonstrated more rapid reso-
lution of HE than in the control group but no mortality 
benefit.
Renal replacement therapy has also been shown to be 
very effective in decreasing ammonia [119]. Compari-
sons of MARS and Prometheus and SMT [209] showed 
that although Prometheus provided increased clearance 
of bile acids and bilirubin, MARS appeared to provide 
greater hemodynamic improvement. In a recent study, 
Sponholz [210] compared MARS and SPAD in a cross-
over design. Both systems were effective in decreasing 
bilirubin and bile acids while increasing albumin binding 
capacity. MARS was more effective at clearing urea and 
creatinine due to the relative flow rates, and the authors 
thus suggested RRT would be required in conjunction 
with SPAD.
Multiple studies of liver support, both biological and 
cleansing have shown benefit with regard to biochemical, 
physiological and mortality end points [211] have shown 
benefit in case series but unfortunately a similar pattern 
has not been seen in controlled trial [212, 213].
MARS compared with standard therapy in a large 
cohort of acute-on-chronic liver failure (AoCLF) in the 
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RELIEF study showed improved biochemical parameters 
but no mortality benefit [214]. Kribben et al. reported the 
effects of plasma separation and adsorption in AoCLF 
[215]; overall therapy did not impact on survival although 
on subgroup analysis benefit was seen patients with a 
MELD > 30.
Various studies involving ELAD systems have been 
undertaken but have not shown mortality benefit.
The MARS system has also been studies in a multi-
center study of ALF in France [216]. For all comers, there 
was no mortality benefit seen, although patients were 
transplanted at a median of 16  h post-randomization 
and listing. MARS therapy was associated with a greater 
chance of transplantation; while predictors of outcome 
were an acetaminophen etiology and lactate.
More recently, a study examining plasma exchange in 
ALF having progressed to grade 2 coma, with an etiology 
of largely acute and hyperacute patients showed a mortal-
ity benefit on intention to treat, with effect being largely 
observed in patients who did not proceed to transplanta-
tion [217].
CO2 removal
ECCO2R (extracorporeal  CO2 removal) systems are dif-
ferent from conventional extracorporeal membrane oxy-
genation (ECMO) systems in terms of blood flow, size 
and type of vascular access and anticoagulation require-
ments. Accordingly, such systems have little influence on 
the level of oxygenation, while they exert mainly a posi-
tive action by the mean of  CO2 removal. Technological 
developments have led to modern venovenous minimally 
invasive ECCO2R systems proposed both for avoid-
ing and shortening IMV in severe acute exacerbations 
(AE) of chronic obstructive pulmonary disease (COPD) 
patients and also for allowing ultra-protective ventilation 
in patients with ARDS. It is generally anticipated that 
technological developments could rapidly increase the 
number of suitable medical devices for minimally inva-
sive ECCO2R. However, ECCO2R systems, even if much 
less invasive than ECMO systems, can carry their own 
complications, mainly in link with vascular access and 
with the anticoagulation regimen.
Stimulating results were reported in recently published 
pilot studies, both in the contexts of ARDS [218, 219] 
and of severe AE of COPD [220–223]. In a proof-of-con-
cept study, Terragni demonstrated in 10 ARDS patients 
that ECCO2R permitted to safely reduce tidal volume 
from to 6.3 ml/kg (IBW) to 4.2 ml/kg [218]. The authors 
also reported beneficial effects on pro-inflammatory 
cytokines measurements and on morphometric pulmo-
nary CT parameters. More recently, Bein reported the 
results of a RCT including 79 moderate-to-severe ARDS 
patients, aiming to establish a reduction in ventilator-free 
days [219]. The authors used of a pumpless arteriovenous 
 CO2 removal system. Overall, the study was negative. 
However, the authors reported a reduction in mortality 
in the more severe patients, as defined by a  PaO2/FiO2 
ration less than 150 mmHg. They also reported less use 
of sedatives and a decrease in the IL-6 plasma level in the 
experimental group. However, they also reported three 
severe complications of the arterial cannulation.
In a multicenter retrospective study including 21 
patients (14 COPD) with acute hypercapnic respiratory 
failure at high risk of NIV failure, Kluge et al. reported a 
low rate of intubation (10%) after initiation of a pumpless 
arteriovenous  CO2 removal system [220]. However, they 
also reported a high incidence of bleedings related to the 
device (two major and seven minor) and one pseudo-
aneurysm. As a consequence, the use of less invasive 
venovenous systems is now generally advocated, in order 
to diminish the rate of device-related complications. 
More recently, Burki et al. reported the results of a pilot 
open study using a venovenous system ensuring  ECCO2R 
of about 80 ml/min (which is close to 1/3 of the average 
value of the physiological  CO2 elimination in normal 
adults at rest) at blood flow rates comprised between 350 
and 500 ml/min [221]. The corresponding vascular access 
was achieved by mean of a specific double lumen 15.5 F 
central venous catheter. In a group of patients at high risk 
of NIV failure, the authors reported that intubation could 
be avoided for all seven patients. Using another device, 
Del Sorbo et al. reported the results of a matched cohort 
study with historical control including in the experimen-
tal group 25 COPD patients with severe AE at high risk of 
NIV failure [222]. Risk of being intubated was three times 
lower (p =  0.047) than in the control group, with intu-
bation rates of 12 and 33%, respectively. Hospital mor-
tality was significantly lower in the experimental group, 
but with large 95% CI: 8% (95% CI 1.0–26.0) versus 33% 
(95% CI 18.0–57.5). All the three previously referenced 
study confirmed the ability of these different devices to 
effectively reduce  PaCO2 values and to increase pH val-
ues [220–222]. Finally, some data are also available with 
regard to the interest of  ECCO2R in already intubated 
COPD patients, either as a primary therapeutic option 
or after NIV failure. In five such severe patients treated 
shortly after intubation, Abrams et al. reported a median 
delay of 4 h (with a maximal duration of 21.5 h) between 
 ECCO2R initiation and extubation [223]. They also 
reported a mean duration of  ECCO2R of 193.0 + 76.5 h 
as well as a mean time to ambulation after  ECCO2R initi-
ation of 29.4 + 12.6 h However, Burki et al. reported less 
positive results in a subgroup of COPD patients placed 
on  ECCO2R much later after intubation [221].
To date, no vast RCT has evaluated the efficacy of min-
imally invasive  ECCO2R either in ARDS or in patients 
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experiencing severe hypercapnic AE of COPD. Such tri-
als are now urgently warranted. Specifically for AE of 
COPD (an acute-on-chronic condition), it will be of great 
importance to assess by such RCTs the efficacy and safety 
of the method on relevant clinical endpoints, not only 
limited to short-term ICU events. If positive, such studies 
could also greatly improve patient-centered outcomes, 
not only limited to the short-term ICU course. It also 
could help to ethically implement such expansive tech-
nologies in the hospital’s practice.
Cell cycle arrest biomarkers: new weapons for a new battle
AKI is becoming an important health concern not only 
because the syndrome is a deadly condition in itself, but 
also because it represents a gateway to CKD [224]. AKI 
is a syndrome with high mortality due to comorbidi-
ties and management challenges, especially in the criti-
cally ill patients [225]. AKI, however, is more than that. 
Even minimal kidney damage due to an insult (exposure) 
in the tubular or glomerular structure may evolve into 
progressive apoptosis and fibrosis and possibly a devas-
tating glomerular destruction with inevitable hyper-fil-
tration of the remnant parenchyma. Thus, AKI is a near 
and present danger that has ramifications for the rest of 
a patient’s life. Several efforts have been made in recent 
years to standardize the definition/classification of AKI 
and, above all, to make an early diagnosis of acute kidney 
damage/dysfunction. This effort has included the discov-
ery and validation of new biomarkers of AKI.
In spite of a growing body of publications, many new 
biomarkers have not yet transitioned to clinical routine 
because of a series of unresolved issues [226]. The first 
is the lack of specificity for AKI of some molecules. The 
amount of false-positive cases associated with elevation of 
the biomarkers caused by acute and chronic comorbidities 
in patients without AKI has often been too high. The sec-
ond is lack of sensitivity of some markers, particularly at 
the earliest stages of kidney injury. A third is the absence 
of clinically relevant and validated cutoff values that help 
guide use of the biomarkers to trigger appropriate inter-
ventions and changes to patient management. In addition, 
a major concern has been that once significant damage has 
occurred, the possibility to modify the clinical course and 
especially the recovery phase was considered minimal or 
absent. The extent to which this may or may not be true is 
unknown, but a significant number of patients with AKI 
are known to recover kidney function [227]. Therefore, the 
general consensus is that at least some kidney tissue can be 
salvaged and earlier detection and intervention are likely 
to benefit the patient. This may be especially true at the 
earliest stages of stress and injury when it may be possible 
to prevent further damage and preserve remaining renal 
capacity, for example, by removing potentially injurious 
exposures such as nephrotoxic drugs and by providing 
extra supportive measures such as heightened attention to 
fluid and hemodynamic management [91].
There is unanimous agreement that a specific plan 
should be undertaken to fight AKI and its consequences. 
A strategic move of the scientific community to prevent, 
protect, diagnose and cure AKI is definitely needed not 
only to save many lives from the acute disorder, but also 
to avoid the evolution into CKD either by reducing the 
level of injury or by facilitating healing and recovery of 
the damaged parenchyma. However, all these approaches 
have been hindered by the lack of reliable methods for 
early diagnosis of the injury and an early identification of 
the patient at risk.
Recently, the US Food and Drug Administration made 
an important step forward in the battle against AKI and 
its consequences. The FDA cleared the marketing of 
the NephroCheck Test (Astute Medical Inc. San Diego, 
USA), a rapid test for the quantitative measurement of 
the cell cycle arrest biomarkers tissue inhibitor of met-
alloproteinase-2 (TIMP2) and insulin-like growth factor 
binding protein-7 (IGFBP7) [228]. The combination of 
the two biomarkers ([TIMP2]·[IGFBP7]) measured by 
the test seems to be highly predictive of which patients 
will develop moderate-to-severe AKI in the next 12–24 h.
Early work in the international multicenter Sapphire 
study of 728 critically ill patients showed that elevation of 
the combination of biomarkers measured by the Nephro-
Check Test is specific to AKI (i.e., is not caused by other 
comorbidities such as sepsis or CKD) and provides a 
strong signal or “renal alarm” to identify when a patient 
is at imminent risk of developing AKI [229]. These uri-
nary biomarkers are believed to be elevated in response 
to renal tubule cell stress or early injury associated with 
the types of exposures known to cause AKI. A primary 
clinical cutoff value (0.3) for the combination of the two 
biomarkers was derived from the Sapphire study data 
and verified in a new cohort of 153 critically ill patients 
(Opal study) [230]. This cutoff was selected to have high 
sensitivity for the primary endpoint of moderate-to-
severe AKI in the next 12 h, with the intent to be used in 
routine clinical practice to identify patients at high risk 
of AKI who therefore are candidates for kidney-sparing 
management strategies such as those outlined in the 
KDIGO guideline for high-risk patients [91]. A second, 
high specificity cutoff (2.0) was selected and verified to 
identify the subgroup of patients who are at the highest 
risk of AKI and who therefore might be appropriate for 
more active interventions. Both cutoffs (0.3 and 2.0) were 
subsequently validated in a 23 site study of 408 critically 
ill patients in the USA (Topaz study) using clinical adju-
dication to determine the primary endpoint of moder-
ate–severe AKI [231].
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The NephroCheck quantitatively measures the 
combination of the two cell cycle arrest biomarkers 
([TIMP2]·[IGFBP7]) both by point of care techniques 
and other laboratory platforms, thus expanding the avail-
ability of the test worldwide [232].
According to the recent publication of the Acute 
Dialysis Quality initiative consensus group [233], there 
is a need for early identification of damage or risk of 
AKI, especially in those patients in which creatinine is 
still negative but biomarkers are positive. In this sense, 
NephroCheck may be used alone, or in combination with 
other biomarkers of AKI as a discriminating test to alert 
physicians. All these considerations assume that put-
ting the diagnostic clock ahead by 12–24 h compared to 
the clinical clock can make a difference. We are particu-
larly convinced that this is the case. Early diagnoses or 
assessment of risk of injury may not only contribute to 
the identification of the cause of AKI and hopefully miti-
gate its effects, but also may help to identify patients in 
which, due to high susceptibility, even a small exposure 
may cause a severe injury. Even a subclinical (creatinine 
negative) injury, which may appear to be negligible, can 
produce a significant parenchymal damage [22]. This may 
be underestimated due to the presence of a significant 
RFRin the kidney and the absence of clinical signs and 
symptoms [23]. The injury, however, reduces the func-
tioning renal mass and produces a progressive increase 
in kidney frailty with a remarkable susceptibility to future 
injuries. This process may be the gateway to CKD.
We must, therefore, use all the tools we have to raise 
the level of patient care and escalate the battle against 
AKI. A reliable, validated and widely available test with a 
specific cutoff threshold has been requested by clinicians 
for a long time. A simple urinary biomarker test to screen 
critically ill patients for the risk of AKI is something that 
is likely to be a useful new weapon in the battle against 
AKI. In this area, FDA has taken an important step to 
provide us with a new tool that is an early alert of which 
patients are at imminent risk. We should take the next 
step in using this new tool to help us improve the care of 
our patients.
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